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Abstract 
The Effects of 7,8-Dihydroxyflavone (7,8-DHF) on Neuroprotection and Neuroplasticity 
Following a Traumatic Brain Injury  
By 
Jennifer Marie Romeika 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University 
Virginia Commonwealth University, 2015 
Advisor: Dong Sun, MD, PhD, Department of Neurosurgery 
 
 Aside from preventing traumatic brain injuries (TBIs) altogether, treatment options for 
TBI typically focus on the secondary biochemical processes that occur in response to the 
primary mechanical insult. These secondary injuries can lead to apoptosis and necrosis in the 
days and weeks that follow a TBI. Therefore, finding a treatment that can prevent, reduce, and 
repair secondary damage is instrumental in the recovery of TBI patients. The flavonoid 7,8-
dihydroxyflavone (7,8-DHF) has been identified as a TrkB agonist that mimics the effects of  
brain derived neurotrophin factor (BDNF). Upon binding to the TrkB receptor, signaling 
cascades are initiated that can promote neuronal survival and neural differentiation. The use of 
7,8-DHF in the treatment of TBI is favorable due to its long half-life and ability to pass the 
blood-brain barrier (BBB). In this study, we evaluated the dosage time frame of 7,8-DHF that 
would allow for the greatest impact in recovery after a focal TBI. Adult Sprague-Dawley rats 
were subjected to a moderate cortical impact injury and administered a 5mg/kg dose of 7,8-
xii 
 
DHF i.p. for five days starting on day 0, 2, 3, or 5 post injury.  Sensorimotor function was 
evaluated with beam walk and rotarod test. Morris Water Maze (MWM) and fear conditioning 
test were used to analyze cognitive function. Biotinylated dextran amine (BDA) was injected 
into the contralateral cerebral cortex 14 days after injury and animals were sacrificed 28 dpi.  
Brain sections were processed for Giemsa histological staining to assess cortical lesion volume 
and the total number of surviving neurons. Parallel sections were processed for BDA staining to 
assess changes of axon sprouting in the injured cortex. VGlut-1 staining of the hippocampus 
was used to identify presynaptic plasticity. We found that the administration of 7,8- DHF 
starting at one hour after TBI could provide protection against motor and cognitive dysfunction. 
Histological examination showed a significant reduction of cortical lesion volume and higher 
number of survival neurons in the injured hippocampus when 7,8-DHF administration began 
one hour and two days after injury. BDA staining of intracortical axon sprouting and VGlut-1 
staining of the hippocampus highlighted a trend that 7,8-DHF administration starting day five 
post brain injury may enhance neuronal plasticity. Collectively, the results indicate that 7,8-DHF 
can provide the better neuronal protection when administration begins one hour after TBI. 
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Chapter One: Introduction 
 
1.1 Definition/Pathophysiology of Traumatic Brain Injury (TBI) 
Traumatic brain injury (TBI) can be described as a loss of brain function due to an external 
mechanical force. The cells and tissue that are directly injured upon impact, including blood 
vessels, axons, neurons, and glia, are considered primary damage (Tsao, 2012). Secondary 
damage is delayed and includes neuronal degeneration in the distal and surrounding regions of 
the impact site. This neuronal degeneration is predominately programmed cell death, or 
apoptosis (Stoica & Faden, 2010) and can be observed in the cortex, hippocampus, and 
thalamus after TBI (Keane et. al., 2001; Stoica & Faden, 2010; Raghupathi et. al., 2000). Many 
biochemical processes, such as excess excitotoxin release, increased intracellular calcium 
concentration, lipid peroxidation, inflammatory mediators, and the production of free oxygen 
radicals, contribute to the secondary damage (Veenith et. al., 2009; Chiaretti et. al., 2008; S. Liu 
et. al., 2014).  A great deal of research and funding has been funneled into TBI research, yet 
treatment options are still limited with much left to be understood about the pathobiology of 
TBI (Yu et. al., 2009). 
1.1.1 Neurodegeneration after TBI 
Secondary damage can occur over days to weeks after TBI (Wagner & Zitelli, 2013) and result in 
diffuse neurodegeneration that affects motor and cognitive function (Hall et. al., 2005). 
Anterograde degeneration can be observed in axons that originate in the ipsilateral injury 
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hemisphere and project via the corpus callosum into the contralateral hemisphere. Retrograde 
degeneration of axons can be seen in neuronal cell bodies that reside in the contralateral cortex 
and hippocampus (Hall et. al., 2005). Caspases, mediators of apoptosis, have been found in the 
thalamus and subcortical region of the injured hemisphere as early as one hour after brain 
injury (Keane et. al., 2001) and at increased levels in the cortex at 24 hours (Clark et. al., 2000). 
Cortical projection neurons in thalamus (Natale et. al., 2002) and predominately immature 
neurons in the granule cell layer of the hippocampus can be observed undergoing apoptosis 
within 24 hours (Zhou et. al., 2012). Widespread hippocampus degeneration occurs at 48 hours, 
affecting the axons that arise from the entorhinal cortex to the dentate gyrus and cornu 
ammonis 3 (CA3) region, the mossy fibers that extend from the dentate gyrus to CA3 pyramidal 
cells, and the axons in the Schaffer collateral pathway that originate in the CA3 region and 
project to the cornu ammonis 1 (CA1) region. Diffuse neurodegeneration in the ipsilateral 
cortex, hippocampus and thalamus has been found to peak between 48-72 hours after brain 
injury (Hall et. al., 2005).  Seven days after injury, dying cells in the hippocampus are 
predominately mature neurons (Zhou et. al., 2012). This culmination of neurodegeneration 
substantially contributes to the tissue damage (Faden, 2002), as well as to spatial memory 
deficits and motor dysfunction that occur after TBI (Hall et. al., 2005). 
1.1.2 Neurogenesis after TBI 
There are two main locations of neurogenesis in the adult brain: the subventricular zone of the 
lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (DG) (Gomazkow, 2012; 
Balu & Lucki, 2009). The first stage of neurogenesis in the hippocampus is proliferation in the 
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SGZ followed by differentiation where the cells become immature neurons and commit to 
neuronal lineage. Then immature neurons will migrate to the granule cell layer (GCL) where the 
neuron will start to make connections by extending an axon towards the pyramidal layer of the 
CA3 and dendrites toward the molecular layer of the dentate gyrus (Bohlen und Halbach, 2007). 
These connections can occur within 4-10 days of birth (Hastings & Gould, 1999). The last step is 
synaptic integration into the hippocampal network (Bohlen und Halbach, 2007) that happens 
around 14 days after birth (Hastings & Gould, 1999). Seven weeks after division, action 
potentials can be generated by the new granule cells (Balu & Lucki, 2009). Cell death of the 
immature neurons has also been observed within 1-2 weeks after birth. If the neuron reaches 
maturity, it can last several months (McDonald & Wojtowicz, 2005).  
Several studies have demonstrated that there is an increase in cell proliferation in the 
hippocampus after TBI (Chirumamilla et. al., 2002; Dash et. al., 2001; Sun et. al., 2005; Rice et. 
al., 2003). This TBI-induced proliferation reached a peak at 2 days post brain injury and 
returned to basal levels by day 14 in fluid percussion injury (FPI) model (Figure 1.1, Sun et. al., 
2005).  While a peak was observed at 3 days post brain injury in a cortical contusion injury (CCI) 
model (Rice et. al., 2003). 
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Figure 1.1. Cell Proliferation in the Ipsilateral Hippocampus in Juvenile and Adult Rats 
Following TBI. Graphs showing increased cell proliferation in the ipsilateral hippocampus at 2 
and 7 days post injury with peak of proliferation occurring at 2 days (Sun et. al., 2005). 
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 1.2 Epidemiology of TBI 
TBI is not only a growing concern in the United States, but affects established and emerging 
countries worldwide (Wagner & Zitelli, 2013). It is a leading cause of disability and death in the 
developed world (Mustafa et. al., 2010). TBI accounts for 50% of the deaths among 15 to 35 
year olds (Kim, 2011). The National Institutes of Health has reported that about 5 million new 
head injuries occur in the United States every year. Two million of these cases result in 
permanent difficulties in employment, education, and family. Around 300,000 individuals will 
require hospitalization and 80,000 will have long-term impairments. Overall, TBIs create an 
economic burden of more than $56 billion yearly (Yu et. al., 2009). Physical impairments due to 
brain injury can limit an individual’s daily functions. Cognition can also be greatly disrupted, 
effecting language, concentration, memory, and attention (Kline et. al., 2002). The causes of TBI 
vary within different age groups and demographics: children under the age of four years old 
have a high rate of TBI due to ‘shaken baby syndrome’, automobile accidents are the prominent 
cause of TBI for 15 – 19 year olds; and the elderly are more likely to have fall-related TBIs 
(Wagner & Zitelli, 2013).  
1.3 Traumatic Brain Injury Model 
Simulation models have been created to gain a better understanding of what occurs during and 
after a TBI. The fluid percussion injury (FPI) and the controlled cortical impact (CCI) injury are 
two of the most common models used because they both induce impairments that resemble 
that of motor and cognitive abnormalities observed in individuals that have experienced a TBI 
(Yu et. al., 2009). Both models are able to produce cell loss in the CA3 and the hilus region of 
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the hippocampus (Fujimoto et.al., 2004), which are common areas to evaluate after a TBI due 
to their sensitivity to injury, role in cognitive functions, and  area of neurogenesis throughout a 
lifetime (Gao et. al., 2009a). The learning and memory deficits that occur as a result of brain 
injury induced hippocampal damage are often considered the hallmarks of TBI (Richardson et. 
al., 2007). 
1.3.1 Fluid Percussion Injury  
The FPI model consists of a fluid pulse that is applied to the dura through a craniotomy window, 
allowing for injury without fracturing the skull (Chauhan et. al., 2010). FPI is able to create 
alterations in intracranial pressure, cerebral blood flow, cerebral metabolism, and disruption of 
blood-brain barrier. The severity of TBI can also be manipulated by adjusting the magnitude of 
impact (Hicks et. al., 1996). However, this method can cause higher rates of morbidity (Chauhan 
et. al., 2010) and has indirect indices from the mechanical loading on the brain produced by the 
fluid pulse, creating more variables and less accuracy with results (Fujimoto et. al., 2004).  
1.3.2 Controlled Cortical Impact 
In the CCI model, a piece of the skull is removed followed by an impact from a electromagnetic 
driven metallic rod. The severity of the TBI is determined and controlled by the depth in which 
the impact rod is driven and the velocity at which it moves (Goodman et. al., 1994). This model 
allows for a focal area of injury that can be easily distinguished (Fujimoto et. al., 2004). Other 
clinical presentations of TBI such as increased intracranial pressure, compression of the brain, 
and brain edema can also be reproduced with the CCI model (Puritt et. al., 2014). The CCI 
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model is able to replicate a more controlled TBI with cortical deformation as would be seen in 
the clinic, making it a good model for preclinical research (Chauhan et. al., 2010). 
1.3.2.1 Determining the Severity of Controlled Cortical Impact  
Impairments in behavioral and cognitive tasks increase with the severity of the TBI. A CCI can 
replicate many clinical symptoms of mild, moderate, and severe TBI just by adjusting the depth 
and velocity of the impact (Yu et. al., 2009). Depth of impact is often the guide to adjusting 
injury severity. Generally speaking, a 2.0 mm impact is considered mild, a 2.5 mm impact is 
moderate, and a 3.0 mm impact is considered severe. However, a reduction of velocity, such as 
3m/sec to 1 m/sec in a 2.5 mm impact could create a deformation not much greater than a 
2mm impact at 5m/sec, demonstrating that these parameters are more guidelines than exact 
predictions (Goodman et. al., 1994).  
1.3.2.2 Cognitive and Motor outcomes with Controlled Cortical Impact 
Animals were able to manifest a range of cognitive and motor tasks that matched the degree of 
brain damage in CCI-injured rat and mouse models. Comparison tests of TBI severity and 
performance in rotarod and Morris water maze (MWM) were able to demonstrate distinct 
levels of cognitive behavioral deficits that corresponded with mild, moderate, and severe TBI. 
Both rats and mice had longer escape latency and impaired recall ability in the probe test of 
MWM and shorter lengths of time on the rotarod as the TBI injury went from mild to severe (Yu 
et. al., 2009).  
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The ability of the CCI model to replicate a range of clinical symptoms in an animal model makes 
it valuable in testing experimental TBI therapeutic drugs. The CCI model also provides a way to 
target a certain patient population, decreasing variables, and ensure that laboratory findings 
can be translated to a clinical population. In addition, the CCI model has provided a way to 
standardize outcomes and parameters of TBI animal models providing validation of 
experimental data and comparison among various research studies (Yu et. al., 2009).  
1.4 Neurotrophins 
A group of polypeptides, called neurotrophins, have been shown to have great influence over 
the survival, development, and functioning of structures in the central nervous system (CNS) 
and peripheral nervous system (PNS). They participate in every stage of creating a neuronal 
network, including the release of neurotransmitters, trafficking of receptors, growth of axons 
and dendrites, maintaining synapses, and aiding in long-term potentiation (LTP). Neurotrophins 
have the ability to moderate single cells and networks through their influences on synaptic 
plasticity and protection. The differentiation, survival, and synaptogenesis of nerve cells is 
influenced by neurotrophins (Gomazkow, 2012). Synthesis of neurotrophins in the CNS occurs 
predominantly by neurons during certain physiological conditions. Both neuronal and non-
neuronal cells synthesize neurotrophins in a precursor, or proneurotrophin, form. These 
immature proteins are then either secreted or cleaved by plasmin or extracellular proteases 
into the mature form (Marco-Salazar et. al., 2014). Cells are able to survive apoptosis, or cell 
death, due to the retrograde flow of neurotrophin from the nerve terminal, up the axon, and 
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into the cell body. The neuron would not be able to maintain a functional differentiated state 
without this continuous retrograde flow of neurotrophin (Skaper, 2012).  
1.4.1 Neurotrophins and Their Receptors 
The diverse effects that occur from the presence of neurotrophins are a result of the ligand-
receptor binding and the specific signal cascades that follow. This includes two transmembrane-
receptor signaling systems that consist of the p75 neurotrophin receptor (p75NTR) and the 
tyrosine kinase receptors: TrkA, TrkB, and TrkC. The p75NTR belongs to the tumor necrosis factor 
receptor super family while the tyrosine kinase receptors belong to the tropomyosin-related 
kinase (Trk) family (Marco-Salazar et. al., 2014). The neurotrophin family of signaling molecules 
include nerve growth factor (NGF), brain-derived neurotrophin factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4 (NT-4). These neurotrophins have binding specificity for particular 
receptors among the Trk family receptors. NGF has a higher affinity for TrkA, BDNF and NT-4 
prefer TrkB, and TrkC binds with NT-3. All of the neurotrophins are able to bind to p75NTR. 
(Marco-Salazar et. al., 2014).  
1.4.2 The Endogenous Response of Neurotrophins after Traumatic Brain Injury 
A significant up-regulation of neurotrophic factors has been observed after an injury to the 
brain (Chiaretti et. al., 2002). Children that demonstrated better outcomes after experiencing a 
TBI had elevated levels of neurotrophins in their cerebral spinal fluid (CSF) (Malik et. al., 2011). 
More specifically, increased levels of the neurotrophin BDNF were found in the CSF of TBI 
patients after injury (Chiaretti et. al., 2002).  TBI animal models were also able to replicate this 
increase of BDNF after a brain injury (Chiaretti et. al., 2008). Studies that have used the direct 
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treatment of neurotrophins to injured brains have been able to demonstrate an upregulation of 
protective genes, such as Ttr, Trh, and CCL-2 (Malik et. al., 2010). However, neurotrophins also 
have their drawbacks due to their limited ability to diffuse in the CNS parenchyma, short half-
lives, and difficulty with being able to permeate the blood-brain barrier (BBB) (Blaya et. al., 
2015). 
1.5 Brain Derived Neurotrophin Factor (BDNF) 
The neurotrophin BDNF has been identified as one of the signaling molecules for neurogenesis, 
promoting differentiation and proliferation of neurons, as well as neuronal survival (Lu et. al., 
2008). Presynaptic BDNF signaling can promote the release of neurotransmitters and 
postsynaptic BDNF signaling can enhance ion channel function (Autry & Monteggia, 2012). 
BDNF has the ability to encourage the branching and elongation of neurons and neurite 
differentiation into axons (Gill et. al., 2013). Overall, BDNF has become one of the most 
important regulators of the survival and differentiation of neurons in the CNS. Many psychiatric 
disorders and neurodegenerative diseases have been associated with changes in BDNF and its 
TrkB receptor, including Alzheimer’s disease, Rett syndrome, Parkinson’s disease, 
schizophrenia, Huntington’s disease, major depressive disorder, and TBI (Bernard-Gauthier et. 
al., 2013). 
1.5.1 BDNF Prevalence and Production in CNS 
BDNF mRNA has the highest expression in the hippocampus, but can be found in many places in 
the brain (Gomazkow, 2012). More precisely, the dentate gyrus of the hippocampus is one of 
the main areas of BDNF production (Lee et. al., 2002). The precursor form of BDNF is 
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synthesized in the endoplasmic reticulum and is hydrolyzed by the matrix metalloptoteases 
plasmin and furin in the Golgi network. At this point, BDNF is packed into secretory vesicles and 
can be found in the presynaptic axon terminals and postsynaptic dendrites (Gomazkow, 2012). 
In an activity-dependent manner, BDNF can be secreted from the post- and pre-synaptic spines 
and terminals (Waterhouse & Xu, 2009).  
1.5.2 BDNF and Its Receptors 
Two different classes of receptors are responsible for mediating BDNF signaling: p75NTR and 
TrkB (Lu et. al., 2008). BDNF has a Kd = 9.9 x 10
-10 M for the TrkB receptor and a Kd ~ 10
-9 M for 
the p75NTR demonstrating its binding selectivity and affinity for each of the receptor types 
(Bernard-Gauthier et. al., 2013). It is through its high affinity for TrkB that BDNF is able to 
provide neuronal survival, neuronal plasticity, and neurogenesis (Lu et. al., 2008). The p75NTR 
receptor is more associated with apoptosis. ProBDNF binds more to the p75NTR receptor while 
the mature form of BDNF has a high affinity to TrkB (Bollen et. al., 2013). However, the mature 
form of BDNF can bind to p75NTR receptor when there are high concentrations of BDNF (Boyd & 
Gordon, 2003). Both of the BDNF receptors can be found in the same cell, coordinating and 
modulating neuronal responses. Furthermore, the signals generated by each receptor can 
augment each other or go against each other, fluctuating between a enhancing and suppressing 
relationship (Kaplan & Miller, 2000).  
 The binding of BDNF to p75NTR induces cell death, or apoptosis. This induced cell death 
has been demonstrated with hippocampal neurons. Neurons lacking Trk receptors are even 
more prone to p75NTR cell death, demonstrating the relationship of TrkB receptor protection 
and p75NTR apoptosis. The p75NTR leads to Jun amino-terminal kinase (JNK) activation and the 
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following activation of Bad and Bim, which eventually leads to the release of caspase-3, -6, and 
-9 (Ichim et. al., 2012).  
 BDNF and TrkB can be found throughout the CNS (Baseri et. al., 2012). The positive 
effects that BDNF has on the synapse are regulated through the TrkB receptor. More 
specifically, BDNF is able to bind to the CC-2 domain, Ig2 domain, and a leucine-rich motif of 
amino acid residues 103-181 of the TrkB receptor (Jang et. al., 2010). The TrkB receptor 
becomes a homodimer upon BDNF binding. Then tyrosine and serine residues on the 
intracellular domain are phosphorylated, activating signaling pathways (Lai et. al., 2012). The 
axons, nerve terminals, and dendritic spines of the granule and pyramidal neurons of 
hippocampus all express the TrkB receptor, elucidating the idea that BDNF works both on the 
pre-and post-synaptic sides (Leal et. al., 2014; Waterhouse & Xu, 2009), but in particular, 
pyramidal cells have high levels of TrkB receptor expression (Dinocourt et. al.,  2006).  
1.5.3 BDNF/TrkB Signaling Pathways 
BDNF and TrkB binding induces the signaling pathways that include mitogen-activated protein 
kinase (MAPK)/Ras pathway, phosphatidylinositol 3-kinase (PI3k)/ serine threonine kinase (Akt) 
pathway, and/or phospholipase C-gamma (PLC-gamma) pathway. These signal cascades play 
important roles in plasticity and survival of neurons as well as neurogenesis (Zhang et. al., 
2014). 
The MAPK pathway stimulates anti-apoptotic proteins, such as B-cell lymphoma-2 (Bcl-2) and 
cAMP-response-element binding protein (CREB). In particular, CREB is required by 
neurotrophins for mediating neuronal survival (Kaplan & Miller, 2000; Wang et. al., 2010). 
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MAPK can also activate extracellular signal related kinase (ERK) (Autry & Monteggia, 2012). 
MAPK pathway leads to further phosphorylation of synapsin I, a protein involved in synaptic 
vesicle clustering and release (Griesbach et. al., 2002). Interfering with the MAPK pathway has 
shown to decrease BDNF-induced synapsin I phosphorylation; thus inhibiting the release of 
neurotransmitters (Waterhouse & Xu, 2009). Ras, a small Guanosine 5’-Triphosphate-binding 
protein, is often responsible for neurotrophin-dependent survival, but it does not have a direct 
effect on survival. Ras turns neurotrophin initiated signals into other multiple signaling 
pathways, including PI3k/Akt and MEK/MAPK (Kaplan & Miller, 2000; Patapoutian & Reichardt, 
2001). Overall, MAPK activation leads to neuronal survival and differentiation (Baseri et. al., 
2012).  
PI3K activates Akt and ERK (Autry & Monteggia, 2012). Akt is able to promote neuronal cells by 
regulating proteins that influence cell survival: including Bad, which inhibits the anti-apoptotic 
protein Bcl-2, pro-caspase-9, and the transcription factor Forkhead that influence apoptosis. 
Overall, Akt’s influence is based on its ability to inhibit apoptotic proteins (Kaplan & Miller, 
2000). Similar to MAPK, PI3K activation also leads to neuronal survival and differentiation 
(Baseri et. al., 2012).  
PLC-gamma leads to an increase in intracellular calcium levels and can activate the 
calcium/calmodulin kinase pathway, which can then activate CREB (Baseri et. al., 2012). When 
activated, PLC-gamma can regulate the development of neurons and the plasticity of synapses 
(Zhang et. al., 2013). 
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1.5.3.1 Current Research on TrkB  
The activation of the TrkB pathways has been shown to improve cognition and has also been 
correlated with an increase in synaptic density (Castello et. al., 2013). Administration of BDNF 
to murine cell lines that were transfected with TrkB showed an activation of the PI3K/Akt 
pathway and reduced apoptosis (Jang et. al., 2010). In the hippocampus, TrkB signaling can 
affect the maturation of dendritic trees and synaptic terminals. TrkB signaling in the 
hippocampus modulates synaptogenesis of the mossy fibers extending from the dentate 
granule cell layer to the hilus and the CA3 region (Otal et. al., 2005). Studies with mice have 
shown that the lack of the TrkB receptor or mutation of the TrkB receptor greatly influences 
synapses in the hippocampus negatively impact learning and memory (Lai et. al., 2012).  
1.5.4 BDNF Influences Synaptic Plasticity 
BDNF and TrkB are upregulated in areas where there is neuronal plasticity occurring. Due to 
this relationship, BDNF is considered a molecular mediator in the function and structure of 
synaptic plasticity and plays a pivotal role in memory formation as well as memory 
consolidation (Zeng et. al., 2012). Even a disruption in the pathway that transports and 
produces BDNF can result in the clinical symptoms of deteriorating memory and cognitive 
dysfunction (Gomazkow, 2012). Many studies have also shown a relationship between lower 
levels of BDNF and cognitive decline observed in aging, schizophrenia, and Rett’s syndrome 
(Bollen et. al., 2013).  
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1.5.4.1 BDNF Influences the Synapse 
The cellular basis for learning and memory is considered to be the synapses in the 
hippocampus. It is the formation of these synapses through dendritic spines that have been 
show to correlate with the ability to learn and recall (Zeng et. al., 2012). Strengthening or 
weakening of the synapses in neuronal networks, which occurs at excitatory synapses, allows 
for information to be represented, processed, and stored (Waterhouse & Xu, 2009).  BDNF 
influences the morphology of mature granule cells and increases the excitatory transmission in 
CA1, CA3, and dentate gyrus (Lee et. al., 2002). BDNF has the ability to regulate this synaptic 
activity and plasticity through structural functional changes in the neurons (Waterhouse & Xu, 
2009), such as axon and dendrite growth and increased exocytosis of synaptic vesicles (Park & 
Poo, 2013). 
1.5.4.2 BDNF and Long-term Potentiation (LTP) 
Long-term potentiation (LTP) is a specific form of plasticity that occurs in the hippocampus and 
is greatly influenced by BDNF (Bollen et. al., 2013; Leal et. al., 2014). The synaptic plasticity that 
occurs at the CA3 and CA1 synapses is involved in the establishment of memories and learning. 
An important characteristic recognized is the increase in secretion and local synthesis of BDNF 
with the increase of synaptic activity. The induction of LTP is also associated with the 
enlargement and formation of spine heads (Lai et. al., 2012). BDNF has the ability to convert 
early LTP to late LTP as well as potentiating subthreshold activation to create LTP (Autry & 
Monteggia, 2012). Much research has been able to demonstrate the importance of BDNF in 
inducting and maintaining LTP. Studies have shown an increase in BDNF mRNA in the 
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hippocampus when learning spatial tasks like that exhibited during the Morris water maze and 
radial maze tests (Lu et. al., 2008). Studies with mice have shown that the absence of BDNF or 
its receptor, TrkB, can have a great impact on the formation of LTP in hippocampal synapses, 
leading to poorer results in certain learning tasks (Leal et. al., 2014; Lai et. al., 2012). In fact, 
hippocampal synaptic plasticity relies heavily on the activation of TrkB receptors (Yang et. al., 
2014).  
1.5.5 BDNF and Its Influence on Neurogenesis 
Neurogenesis and neuronal protection signal cascades area initiated when BDNF binds to its 
TrkB receptor. Research has demonstrated that with the treatment of BDNF, neurogenesis can 
be stimulated in the dentate gyrus (Gomazkov, 2012). Rats that were infused with BDNF were 
observed to have neurogenesis of the granule cells, which occurred contralaterally to infusion 
site, indicating a wide spread effect on the hippocampus (Scharfman et. al., 2005). 
Neurodegenerative disorders, TBI, and brain ischemia studies have been able to show the 
initiation of neurogenesis. In these studies, new neuronal cells could be found in the areas of 
damage, attempting to replace tissue structures that were no longer viable (Gomazkov, 2011). 
BDNF also has the ability to activate the synthesis of proteins that will protect the 
differentiation of progenitor stem cells into mature neurons, making BDNF a valuable asset in 
the survival of cells created during neurogenesis (Gomazkov, 2011). Neuronal survival has also 
been shown to decrease with the reduction of BDNF and TrkB activity (Salranen et. al., 2005). 
This relationship of BDNF and neurogenesis provides another reason to study the promising 
therapeutic effects of BDNF and its receptor TrkB (Gao et. al., 2009b).  
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1.5.6 BDNF and Its Relationship with TBI 
TBI research continues to demonstrate the neuronal protective and neuronal plasticity effects 
of BDNF. The presence of increased levels of BDNF after TBI is indicative of the brain’s attempt 
to provide neuroprotection against biochemical and molecular changes induced by a TBI 
(Chiaretti et. al., 2002). BDNF binding to the TrkB receptor has shown to have neuroprotective 
effects after several types of brain injury (Hicks et. al., 1998). Mice knockouts models indicate 
that BDNF can provide neuroprotective and repair function, trying to regain the connections. 
Studies have shown an increase in cortex and hippocampal BDNF mRNA after an experimental 
TBI of moderate severity, lasting from several hours to days after the injury (Kaplan et. al., 
2010). After a unilateral FP injury, expression of BDNF mRNA has also been observed to 
increase bilaterally in the dentate gyrus granule cell layer and CA3 pyramidal cell layer (Hicks et. 
al, 1997). BDNF mRNA has been observed to increase in the hippocampus as soon as one hour 
after a FPI or CCI and can remain elevated for as long as 72 hours after the TBI (Hicks et. al., 
1998). BDNF and TrkB expression have also been found to be upregulated after Schaffer 
collateral injury. Axonal sprouting of the pyramidal neurons in the CA3 region of the 
hippocampus can occur near the site of injury. Blocking BDNF attenuates these morphological 
and functional changes (Gill et. al., 2013). 
1.6 Vulnerability of the Hippocampus after TBI 
The hippocampus is often a common area to evaluate after a TBI due to its vulnerability, role in 
cognitive function, and being one of the few areas in the brain that undergo neurogenesis 
throughout a lifetime (Gao et. al., 2009a). Bilateral loss of hippocampal neurons has been 
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observed in 85% of fatal human TBI cases, indicating that hippocampal atrophy is a major 
consequence of TBI. This neuronal was repeatedly demonstrated in animal studies where TBI’s 
were induced, including nonhuman primates, rodents, and pigs (Royo et. al., 2007). Magnetic 
resonance imaging (MRI) studies demonstrated this hippocampal reduction in both children 
and adults after a TBI. Secondary damage can be attributed to this pathological response (Ariza 
et. al., 2006).   
In particular, a major area of concern when it comes to cell loss in the hippocampus is the CA3 
region. Hippocampal CA3 pyramidal cells are the most sensitive to damage. Cell death can lead 
to deficits in learning, memory, and cognitive impairment (Malik et. al., 2011). It is the 
hippocampus that is responsible for long-term potentiation (LTP), involved with memory and 
learning. As mentioned before, BDNF plays a role in this hippocampal signaling and contributes 
to the mediation of LTP (Leal et. al., 2014).  
Neural stem/progenitor cells in the SGZ of the dentate gyrus are continuously generating new 
neurons. These neural stem/progenitor cells have the potential to repair damage done to the 
hippocampus after a TBI (Gao et. al., 2009a). However, these hippocampal progenitor cells are 
also more vulnerable to apoptosis (Gomazkov, 2011). Permanent deficits in learning, memory, 
and cognitive abilities can result from the cell death that occurs in the hippocampus after a TBI. 
Protection and regeneration of these cells has become one of the focuses of TBI research due 
to the debilitating effect of their loss. However, at this time there is no proven therapeutic 
technique or medicine in treating a TBI and preventing the cognitive impairments that may 
result (Malik et. al., 2010). 
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1.7 The Molecule 7,8-Dihydroxyflavone (DHF) 
Insufficient BDNF has also been thought to play a role in neurodegenerative diseases including 
Parkinson’s, Huntington’s, Depression, and Alzheimer’s (Baseri et. al., 2012). Due to its valuable 
role in neuronal survival, neurogenesis, and neuronal plasticity, BDNF has become an attractive 
target in the use of therapeutic treatment for cognitive disorders and TBI. However, it also has 
a poor pharmacokinetic profile that restricts its therapeutic potential, causing the research 
community to find an alternative molecule that can stimulate the positive effects initiated by 
BDNF (Bollen et. al., 2013). Compounds known as flavonoids have become a focus of interest 
due to their potential to provide neuronal protection, enhance existing neuronal function, and 
stimulate neurogenesis (X. Liu et. al., 2010). The screening of chemical libraries has resulted in 
the discovery of a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF), which mimics BDNF (Zeng 
et. al., 2012).  
The molecule 7,8-DHF can bind to TrkB receptors with high affinity and has the added 
advantage of being able to enter the brain with more efficacy than BDNF, making it a viable 
alternative to BDNF in therapeutic treatment (Zeng et. al., 2012; Wu et. al., 2014). The 
flavonoid, 7,8-DHF is part of a polyphenolic compound family found in fruits and vegetables. 
Other flavonoids, such as 3,6-dihydroxyflavone, 3,7-dihydroxyflavone, have also shown to 
protect against neuronal cell death, stimulate the process of neuronal regeneration, and also 
enhance the function of neurons. However, 7,8-DHF mimics BDNF due to its ability to bind to 
TrkB, resulting in neuronal survival, differentiation, and neurogenesis (Chen et. al., 2011). Not 
only does 7,8-DHF have the potential to be a therapeutic tool in the treatment of neurological 
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disease (Jang et. al., 2010) it could also become valuable in the treatment of TBI (Wu et. al., 
2014). 
1.7.1 Pharmacokinetics of 7,8-DHF 
BDNF is not a viable therapeutic agent due to its short half-life, poor delivery and inability to 
easily cross the BBB (Wang et. al., 2014). BDNF is quickly cleared from circulation with a half-life 
of less than ten minutes. The BBB has the ability to be permeable to molecules with the size of 
about 180 daltons or less, unfortunately, BDNF with its molecular weight of 27 kilodaltons is far 
too big to easily cross the BBB (Baseri et. al., 2012). Compared to BDNF, 7,8-DHF is not only 
smaller but also very potent. It is able to pass through the BBB with ease (Bollen et. al., 2013) 
when administered orally or intraperitoneal (Wang et. al., 2014). The molecular mass of 7,8-
DHF is less than 1% of the size of active BDNF, measuring at 254 Da. The binding of 7,8-DHF to 
the TrkB extracellular domain activates signal cascades that can last for hours without causing 
degradation of the internalized receptor (X. Liu et. al., 2014). In one study, the bioavailablity of 
7,8-DHF was about 5% with a half-life of 134 minutes given orally at 50mg/kg  (Zhang et. al., 
2014). It has a low cellular EC50 of 35 nM with a 5 mg/kg dosage. The ligand to receptor ratio 
resulted in 1:1 ratio (Jang et. al., 2010).  In another study that used surface plasmon resonance 
(SPR), the Kd for BDNF was 1.7 nM while 7,8-DHF was 15.4 nM. Fluorescence spectroscopy also 
revealed a Kd of about 12 nM. Both experimental studies demonstrated 7,8-DHF’s specificity for 
the TrkB receptor (X. Liu et. al., 2014).  
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1.7.2 TrkB and 7,8-DHF 
7,8-DHF is a selective TrkB agonist. It is able to activate TrkB receptors without binding to p75 
receptors, allowing for the mediation of signaling pathways that influence neuroprotection and 
neurogenesis neglecting the activation of the apoptotic processes (Bollen et. al., 2013). 7,8-DHF 
does not bind to the extracellular domain (ECD) or intracellular domain (ICD) of the p75 
receptor. It is able to autophosphorylate TrkB selectively without the autophosphorylation of 
TrkA or TrkC. Overall it has a high affinity for the ECD of TrkB indicating a strong binding 
specificity (Jang et. al., 2010). 
When administered intraperitoneal (IP), 7,8-DHF was able to activate brain TrkB, establishing 
that it can cross the brain-blood barrier. 7,8-DHF was able to induce the autophosphorylation of 
TrkB, which lead to the activation of MAPK, PI3/Akt, and Erk1/2 signal pathways in a time frame 
that was comparable to BDNF and in a dose-dependent manner (Jang et. al., 2010; Z. Liu et. al., 
2010). Furthermore, the activation of TrkB receptors through 7,8-DHF did not result in the 
ubiquitination or degradation of receptor which occurs when TrkB is activated by BDNF. Binding 
results in the internalization of the TrkB receptor and ligand complex and eventual formation of 
signaling endosomes (X. Liu et. al., 2014). Daily administration of 7,8-DHF to mice in a 
Alzheimer’s model exhibited a partial rescue of down-regulated TrkB receptors in the 
hippocampus. However, the wild-type litter mates in this study did experience a down-
regulation of TrkB receptors, indicating that there may be a compensatory reaction to 
continuous exposure to agonist (Devi & Ohno, 2012). 
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In murine cell lines transfected with TrkB, the binding of 7,8-DHF to the TrkB receptor 
prevented apoptosis, with similar results to BDNF binding in the same cells. Mice hippocampal 
cells presented a decrease in apoptosis to kainic acid when also administered with 7,8-DHF. 
TrkB receptor was activated by 7,8-DHF in a knock-out mouse model that had a BDNF-depleted 
cortex. Reduced infarct volumes were also observed in a stroke model mice that received 7,8-
DHF. This reduction of apoptosis and decrease infarct volume demonstrate the protective 
ability of TrkB signal pathways via 7,8-DHF (Jang et. al., 2010). 
1.7.3 Current Experimental Findings of 7,8-DHF 
In particular, 7,8-DHF has neurotrophic activities that are associated with Parkinson’s disease 
(Chen et. al., 2011), Alzheimer disease (Castello et. al., 2013), Huntington disease, stroke, (X. Liu 
et. al., 2014), Depression, and Rett syndrome(Liu et. al., 2012). Reduce tissue damage, 
apoptosis, brain edema, and an increase in neuronal protection was observed in a TBI mouse 
model that administered 7,8-DHF at various time points after brain injury (Wu et. al., 2014). 
Overall several studies have been able to show the diversity of neuroprotection and plasticity 
that 7,8-DHF can play in various neurological diseases and disorders (Liu et. al., 2012). 
1.7.3.1 Neuronal Protection and 7,8-DHF  
In several experimental models, 7,8-DHF has demonstrated that it was able to enhance 
neuronal survival through anti-apoptotic means. These models include the survival of retinal 
ganglion cells, motorneurons, dopaminergic neurons in Parkinson disease (X. Liu et. al., 2014), 
as well as cerebral neurons in focal ischemia model (Wang et. al., 2014). 7,8-DHF has been 
shown to exhibit potent protective effects in a oxygen-glucose deprivation environment in a 
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dose-dependent manner. It was able to protect rodent and human neurons from hydrogen 
peroxide-induced apoptosis. 7,8-DHF blocked glutamate-provoked caspase-3 activation in mice, 
again showing that is able to protect through the repression of neuronal apoptosis via TrkB 
(Jang et. al., 2010).  In addition, 7,8-DHF has also been demonstrated to attenuate ischemic 
cerebral injury by inhibiting cell apoptosis, via down-regulation of caspase-3 and Bax and up-
regulation of Bcl-2. Caspase-3, the executioner of programmed cell death, when activated will 
lead to DNA fragmentation. Bax is a pro-apoptotic interacelluar protein while Bcl-2 is a anti-
apoptotic protein (Wang et. al., 2014). 
1.7.3.2 The Effects of 7,8-DHF on Cognition and Motor Function 
Deficits in memory due to age, stress or genetic background, have been shown to improve with 
the treatment of 7,8-DHF, with dosages of i.p. 5mg/kg. However, memory also improved in 
healthy, young rats that received low doses of 7,8-DHF (p.o. 0.1-3 mg/kg) (Bollen et. al., 2013). 
Chronic application of 7,8-DHF was able to restore behavioral performances and spatial 
learning and memory in aged rats that had impaired cognitive and motor capabilities (Zeng et. 
al., 2012).  In a Alzheimer mouse model, 7,8-DHF mice showed improved hippocampus-
dependent behavior via the MWM (Castello et. al., 2013). Animal models demonstrated that 
7,8-DHF plays an important and positive role in learning and memory. An injection of 7,8-DHF 
was able to strengthen their emotional learning ability in normal rats. Chronic administration of 
7,8-DHF was able to restore deficits in memory in aged rats and in Alzheimer rat models. Even 
pretreating with 7,8-DHF in rats that were immobilized to provoke stress had improved long-
term spatial memory compared to their untreated counterparts. The working learning deficits 
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that are seen in schizophrenia rat models were also reversed with chronic treatment with 7,8-
DHF (Yang et. al., 2014).  
1.7.3.3 The Effects of 7,8-DHF on Neuronal Plasticity 
Changes in neuronal synapses are often used to measure the plasticity of the brain. The 
synapse is also considered to be the cellular component of learning and memory. The number 
and density of dendritic spines along the pyramidal neurons in the hippocampal CA1 region had 
increased in aged rats treated with 7,8-DHF, suggesting that 7,8-DHF assists in the formation of 
synapse. 7,8-DHF increased the induction of LTP, indicating that 7,8-DHF could be used to 
target plasticity in the hippocampus and improve memory. 7,8-DHF administration also rescued 
spatial memory and synaptic plasticity in cognitively impaired aged rats (Zeng et. al., 2012). 
High-frequency stiumulus-induced synaptic potentials in the hippocampus were enhanced with 
7,8-DHF. TrkB receptor phosphorylation in hippocampal neurons, which are associated with 
plasticity, learning, and memory were increased with 7,8-DHF (Yang et. al., 2014). Activated 
TrkB receptors observed in the dentate gyrus after chronic treatment of 7,8-DHF indicate that 
the TrkB agonists ability to promote neurogenesis by promoting the proliferation of progenitor 
cells (X. Liu  et. al., 2010).  
1.8 Summary and Hypothesis  
TBI is a leading cause of disability and death worldwide (Wagner& Zitelli, 2013) with 5 million 
new head injuries occurring in the US every year (Yu et. al., 2009). After the initial mechanical 
impact, secondary damage continues to evoke neurodegeneration in the form of apoptosis that 
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further affects motor and cognitive function (Zhou et. al., 2012). A rise in BDNF and its TrkB 
receptor has been considered to be an endogenous response to the damages that occur with 
brain injury (Chiaretti et. al., 2002). This increase of BDNF and TrkB leads to the initiation of 
signal cascades that mediate neuronal protection, neuronal plasticity, and neurogenesis (Lu et. 
al., 2008).  
The flavone derivative 7,8-DHF was discovered in hopes of finding a molecule that could mimic 
BDNF and bind to the TrkB receptor. Since its discovery, 7,8-DHF has been documented in 
providing neuroprotection and neuroplasticity in various neurological diseases and disorders 
(Liu et. al., 2012). Unlike BDNF, 7,8-DHF has a much longer half-life and can easily pass the BBB, 
making it a possible alternative in treating TBI (Zeng et. al., 2012; Wu et. al., 2014).  
This study addressed the effects of 7,8-DHF on neuroprotection and neuroplasticity after TBI. It 
is hypothesized that 7,8-DHF will have the ability to provide neuroprotection and 
neuroplasticity after a TBI and this will vary according to time given after TBI. 7,8-DHF will 
provide neuronal protection when administration begins one hour and two days after brain 
injury, based on the time frame of previous documented neurodegeneration in the brain after 
TBI. The protective aspect of DHF treatment will be quantified using contusion volume, motor 
and cognitive recovery, and hippocampal cell numbers. 7,8-DHF will provide neuronal plasticity 
when administration begins three days and four days after brain injury, based on the time 
frame of synaptic regeneration. The plasticity aspect of DHF will be quantified using neuronal 
tracers/axon sprouting, motor and cognitive recovery, and synaptic markers.  
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Chapter Two - Methods and Materials 
 
2.1 Experimental Animals 
All the animal care and experimental procedures were in accordance with the National Institute 
of Health Guide for Care and Use of Animals and approved by the Institutional Animal Care and 
Use Committee at Virginia Commonwealth University. Male Sprague Dawley rats (300-350g; 
Harlan Laboratories) were housed in pairs, maintained in a 20-22 degree Celsius environment 
with a 12 hour light/dark cycle and fed ad libitum with standard rodent chow. Animals were 
acclimated to environment for at least one week prior to behavioral tests and surgeries. A total 
of 52 Sprague Dawley rats were used in this experiment. Animals were randomly assigned to 
one of six groups (Table 2.1): Sham group (n= 8), Vehicle group which received a CCI injury and 
vehicle treatment (n=13), Group 1 which received CCI + DHF treatment starting day one post 
injury (n=10), Group 2 which received CCI + DHF treatment starting day two post injury (n=8), 
Group 3 which received CCI + DHF treatment starting day three post injury (n=8), or Group 4 
which received CCI + DHF treatment starting day five post injury (n=5).   
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Animal Treatment Groups 
Sham  
Vehicle + 
CCI 
Group 1 ,         
DHF 0-4 
dpi 
Group 2 ,          
DHF 2-6 
dpi 
Group 3,          
DHF 3-7 
dpi 
Group 4 ,          
DHF 5-9 
dpi 
Total 
8 13 10 8 8 5 52 
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Table 2.1 Animal Treatment Groups in 7,8-Dihydroxyflavone Study. Table showing the number 
of animals in each treatment group. 
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2.2 Controlled Cortical Impact (CCI) Injury 
A total of 44 male Sprague-Dawley rats at the age of 3 months old received a controlled cortical 
impact injury (CCI) using a Benchmark Stereotaxic Impactor (Figure 2.1). Animals were 
anesthetized with isoflurane (2.5% in 30% O2 and 70% Nitrogen) and remained sedated 
throughout surgical procedure. To ensure sedation, a tail-pinch or paw-pinch reflex was 
administered every ten to fifteen minutes. Once sedated, the scalp was shaved where injury 
would be made. Rats were placed in a stereotactic frame attached to the impactor.  The head 
was maintained at a horizontal position via ear bars and jaw fixed to biting plate. To protect 
corneal membranes during surgery, an opthalmic lubricant ointment was applied to eyes. 
Betadine was applied prior to making a midline incision to the skin above the skull with a sterile 
scalpel-blade. The skin, fascia, and temporal muscles were reflected bilaterally and held back 
with hemostats, keeping skull exposed during procedure. A 3.5-mm circular craniotomy was 
performed on the left side at 2mm lateral to the mid-sagittal suture and 2-mm below the 
bregma with a stainless steel trephine and Burr-Drill. A 3-mm rigid impactor (Leica Benchmark 
Stereotaxis Impactor) was driven by an electromagnetic piston and applied perpendicularly to 
the exposed dura mater, moving at 3.5 m/sec. The zero point was obtained by lowering the 
impactor tip until it reached the dura mater. The injury was induced by a 2.5-mm depression 
that remained in cortical tissue for 500ms. After the injury, the incision was closed with an 
absorbable suture, single stitch and Lidocaine Hydrochlorid Jelly USP 2% and Bacitracin was 
applied to the sutured area. Animals that were part of the sham group, received an identical 
anesthesia and surgery without brain injury. Animals maintained a body temperature of 37 
degrees using a thermostatically controlled heating pad. Once paw and tail reflexes were 
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regained and normal breathing was observed, animals was transferred to cage to be monitored 
for discomfort or distress before returning to housing area.  
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Figure 2.1 Controlled Cortical Impact Injury Device. Photograph of the device used to deliver 
the controlled cortical impact injury (CCI) to Sprague-Dawley rats. 
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2.3 TrkB agonist, 7,8-Dihydroxyflavone (7,8-DHF), Administration  
The small molecule flavonoid, 7,8-Dihydroxyflavone (7,8-DHF,) has the therapeutic potential for 
TBI and other neurological diseases such as amyotrophic lateral sclerosis, Parkinson disease, 
and Alzheimer’s disease (Jang et. al., 2010; Wu et. al., 2014). Due to its ability to mimic BDNF by 
binding to TrkB receptors and initiating signal cascades, it can influence neuronal survival, 
neuronal differentiation, and neurogenesis (Chen et. al., 2011).  
Animals receiving DHF treatment were administered 5mg/kg of 7, 8 DHF intraperitoneal (IP) of 
single doses for 5days/doses starting at the following 4 regimes: Group 1 received DHF given 0-
4 dpi, starting at 1 hour post injury (n=10), Group 2 received DHF given 2-6 days post injury 
(n=8), Group 3 received DHF given 3-7 days post injury (n=8), Group 4 received DHF given 5-9 
days post injury(n=5). A total of 31 injured animals received 7,8-DHF.  
To prepare 7,8-DHF for injection, 7,8-DHF was weighed out and dissolved  in DMSO, then added 
to sterile PBS. The final vehicle composition was 17% DMSO in sterile PBS (v/v). 7,8-DHF was 
mixed with the vehicle at the concentration of 10mg/ml. Animals received intraperitoneal 
administrated of 5mg/kg of 7,8-DHF using a 26 gauge needle. The Sham Group received a 
vehicle(n=8). The Sham group and the CCI + Vehicle group received vehicle (17% DMSO) 
injection only. Lastly the CCI with vehicle group received 15% DMSO given 0-4 days post injury 
(n=13).  
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2.4 Motor Function Tests:  Beam Walk and Rotarod Tests 
Behavior tests add another level of measurement when determining the severity of a TBI and 
the effects of therapeutic treatment. Any motor deficit consequences were measured by 
evaluating simple reflexes with the beam walk and rotarod. These tests are able to evaluate the 
balance, coordination, and walking of animals, and mimic everyday activities. Since these are 
not reflexive behaviors, they require pre-surgery training to ensure that the animal has learned 
the task and has become acclimated to environment of the test. The pre-injury results become 
the baseline for the animal. The beam walk task is able to assess the animal’s coordination of 
muscular movements in order to maintain equilibrium. It is able to test simple, gross 
vestibulomotor function and balance/cerebellar function (Fujimoto et. al., 2004). The rotarod 
task also has the ability to detect motor impairments. It has also been able to demonstrate a 
higher sensitivity in motor analysis and dysfunction after a TBI compared to the beam walk task 
due to the increasing challenge of the animal to maintain equilibrium at increasing speeds 
(Hamm et. al., 1994). All animals were administered behavioral tests. 
2.4.1 Beam Walk 
 During the beam-walk task, the rats were trained to move away from a bright light paired with 
a loud white noise. The rats would move horizontally across an elevated 100-cm long and 1.5cm 
wide narrow beam with the light and noise on one end and a darkened box at the other end. At 
equal distances and alternately placed on either side of beam, four pegs of 3mm diameter 
protrude upwards from beam, forcing the rat to move around these pegs to get to darkened 
box. Rats were first trained on beam by placing them facing and closer to the darkened box 
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until the rat could travel the entire length of the beam. During training, once the box was 
reached, the rat was allowed to stay in box for 60 seconds. The rat was considered trained in 
the beam walk task when he was able to cross the beam under 10 seconds for three 
consecutive times. For the testing part of the beam-walk, the rats were placed on the end of 
the beam near the light and noise source and timed until it reached the darkened box. During 
testing, the animal was allowed to remain in box for 30 seconds. The behavior was assessed by 
the latency of the animal being able to reach the darkened box. Again, this was tested three 
consecutive times. The timer was stopped when rat’s body entered the box. The maximum 
amount of time that a rat could attempt beam-walk was 60 seconds. If the animal fell off or 
jumped off beam, his score was documented at 60 seconds. Training was administered one day 
prior to CCI. Testing of beam-walk occurred at 1, 3, 5, and 7 days post injury.  
2.4.2 Rotarod 
The rotarod instrument consists of a wheel made of 1mm stainless steel rods that spin around 
via motor. There are 18 rods that create a cylindrical shape.  When placed on the wheel, the 
animal is able to grip the rods with his paws, changing his footing on the rods while it is 
rotating.  A Plexiglas disc is on either side of the wheel, framing the area where the animal is to 
walk. Adjacent to the wheel is a control box that can be used to control speed, direction, 
rotational direction, and brake. The goal of the task is for the animal to walk on the rods/rungs 
while the rods/rungs are rotating without falling off at an increasing speed until 30rpm is 
reached. Initially, the animal is placed on the wheel for ten seconds at 0 rpm. After the wheel 
begins to rotate, it increases in speed at about every 15-20 seconds, adding to the sensitivity of 
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the task. The animal is timed, starting when the wheel begins to move, until he falls completely 
off the rotating wheel or is able to continue walking on wheel for 120 seconds. If the animal 
turns around on the wheel twice or grips rungs and rotates with wheel for two consecutive 
rotations, it is considered a fall and the timer was stopped, indicating the animal’s score. 
Training of the rotarod occurred day prior to CCI. Testing of rotarod was administered at 1, 3, 5, 
and 7 days post TBI. 
2.5 Cognitive Function Tests: Morris Water Maze (MWM) and Fear conditioning 
Cognitive dysfunction is another layer of trauma that occurs after a TBI. Two common methods 
to evaluate cognitive dysfunction are the Morris water maze (MWM) and the fear conditioning 
test. A total of 52 Sprague-Dawleys were administered cognitive tests. Of those 52 rats, 8 were 
part of the Sham group, 13 were part of the CCI + Vehicle group, 10 were part of Group 1 (CCI + 
DHF given 1-4 dpi), 8 were part of Group 2 (CCI + DHF given 2-6 dpi), 8 were part of Group 3 
(CCI + DHF given 3-7 dpi), and 5 were part of Group 4 (CCI + DHF given 5-9). 
2.5.1 Morris Water Maze (MWM) 
For the TBI model that uses a CCI in rats, mazes are sensitive enough to detect the severity of 
the injury and the efficacy of therapy. Behavioral tasks, such as mazes and boxes, allow for non-
verbal animals to be assessed for cognitive deficiencies. In order to complete a maze, there 
must be a visuospatial memory created and then recalled during completion. In the case of the 
MWM, it is a versatile maze that can be used to test retrograde amnesia or memory, 
anterograde amnesia or learning, spatial reference memory, spatial working memory, and 
motor deficit. The ability to use spatial navigation and create episodic memories is 
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hippocampally mediated. The prefrontal cortex mediates the functions involved with learning 
the ways to solve a problem, for example swimming to platform. Therefore, the MWM can be 
used to evaluate damage that has occurred in several areas of the brain due to TBI (Fujimoto et. 
al., 2004).   
The MWM consists of a round water tank that is six feet in diameter and three feet deep. 
Permanent extra-maze cues were placed in room on the walls i.e. book shelf and pictures on 
walls. The tank was filled with 12cm of water and made opaque with 500ml of white latex 
paint. The water temperature was maintained at approximately 22.2 degrees Celsius. A 
platform that is 11cm tall is placed in one of the four equal quadrants. The appearance of the 
platform is concealed due to the opaque water. To allow for recovery of residual motor deficits, 
animals were tested on days 12 through 16 after TBI. The animal was tested by placing him in 
tank, facing the wall of the tank in one of the four quadrants, consisting of north, south, east, 
and west, which was randomly picked. The platform was placed in the south-west quadrant 
25cm from the rim of the tank. For each trial, a new starting point, or quadrant was picked until 
the animal had completed four trials for each of the five days. The animal was allotted 120 
seconds to find the platform and once it was reached the animal would rest on the platform for 
30 seconds. If the animal was unable to find the platform in 30 seconds, then he would be 
taken out of the water and manually placed on the platform for 30 seconds. A computerized 
video tracking system monitored and recorded the paths of the animal. That latency time to 
find the platform and the path length were analyzed to determine cognitive deficits. The longer 
the animal took to reach platform indicated a deficient in learning function. A probe trial is a 
measurement for memory function which was conducted 24 hours after the last of latency test 
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which involved removing the platform and letting the animal swim in tank for 60 seconds. 
Measurements of the time that the animal spent in the quadrant where the platform was prior 
were recorded.   
2.5.2 Fear Conditioning 
Fear conditioning uses associative learning to determine the degree of cognitive dysfunction. 
Associative learning is pairing of a conditioned stimulus (CS) with a an unconditioned stimulus 
(US) that leads to conditioned response (CR), which can be elicited without the presence of the 
US. In the case of fear conditioning, a tone (the CS) is paired with a footshock (the US) and 
freezing behavior, or a refraining of movement, is evoked (CR). The freezing behavior, with the 
exception of movement due to respiration, has been documented as a behavioral response to 
fear in rodents. Initially, the animal has no fear-like response to the tone and continues to move 
around the cage in an un-effected manner. After pairing, the animal will freeze when the tone is 
heard even when the footshock does not occur. It is an indication that the animal has learned 
that the sound of a tone will result in an aversive stimulus, a shock. Measuring the freezing time 
when the animal is in the box and when he hears the tone, allows for the evaluation of fear 
memory (Lai et. al., 2012). 
Animals were placed in a Plexiglas chamber with a stainless steel grid bottom. The chamber is 
equipped with a light, video camera, and speaker. The stainless steel bars are able to 
administer a shock to the animals’ feet. The video camera allows for the monitoring and 
recording of the animal’s movement. On day one of fear conditioning, animals were allowed to 
acclimate themselves with the chamber for about 120 seconds. After 120 seconds, a tone was 
presented for 30 seconds. Delay conditioning is conducted by presenting a mild electric shock 
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with duration of 0.5 seconds administered to the animal’s feet through the grid floor at the end 
of the tone on the first day of training. On day two of fear conditioning, the animal was placed 
in the chamber again for a total of 300 seconds with no tone or administration of shock. Four 
hours after the test with no tone or shock, the animal is placed in chamber again for a total of 
180 seconds. A tone is presented towards the end of the time in the chamber during this time, 
starting at 120 seconds and lasting for 60 seconds. Experimenters remained silent throughout 
all experiments to avoid associative learning with additional sounds other than the tone. The 
amount of time that the animal refrained from moving, or freezing behavior, was measured on 
day two of experiment, including the 300 seconds without tone or shock and the 180 seconds 
with tone. Respiration movement was exempt from calculations. Testing of Fear Conditioning 
was administered on days eight through nine post CCI. 
2.6 Tissue Processing 
After completing behavior tests, animals were sacrificed at 16 or 28 days post injury. Animals 
were deeply anesthetized with isofluorane inhalation and transcardially perfused 400ml of 1x 
phosphate buffer solution (PBS) and then perfused with 400 ml of 4% paraformaldehyde in PBS. 
Solutions were made on the day of sacrifice. After opening the animal’s skull, brains were 
removed and post-fixed with 4% paraformaldehyde in PBS at 4˚C. Post-fixation occurred for a 
minimum of 48 hours, after which, brains were sliced using a Leica vibratome. Starting at the 
rostral end of the brain, coronal sections were cut into 60 or 50 µm thick sections for a total of 
120 sections collected from each brain. Once sliced and collected, brain tissue sections were 
placed in five 24-well plates with each well containing PBS + 0.02% sodium azide. All tissue 
sections were stored at 4˚C in a refrigerator until needed for staining procedures.  
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2.7 Immunohistochemistry: Giemsa, Biotinylated Dextran Amine (BDA), and VGlut1 
2.7.1 Giemsa Staining 
Giemsa is a dye that is able to stain the phosphate groups of DNA. It more predominately 
attaches to regions that have adenine-thymine bonding and is often used to identify 
chromosomes (Prainsack et. al., 2014). Giemsa histological staining was used to determine the 
total lesion volume induced by CCI and the number of neurons that were present in different 
areas of the hippocampus.  
Brain tissue sections spanning the rostro-caudal extent of the hippocampal dente gyrus area 
were selected for staining. These sections were relative to the coordinates of -2.5 to -5.2 from 
the Bregma according to the Paxinos and Watson stereotaxic rat atlas (Paxinos & Watson, 
1986).  
The tissue sections were mounted on microscope slides and dried overnight, then processed 
with Giemsa histochemical staining. The tissue sections were immunostained with Giemsa in 
the following manner: 10% Giemsa solution made from Giemsa stock solution (EMS, #26156-
01) 30ml, distilled water 270ml, and 400ul of 0.5% acetic acid. Giemsa solution was filtered, 
heated to 60˚C, and poured into a staining pot. Tissue sections were first soaked in running tap 
water for three minutes before putting them in warmed Giemsa solution and incubated for 45 
minutes at 60˚C. Then sections were rinsed in running tap water for two minutes. After rinse, 
tissue sections were dipped in a differentiation bath of 0.5% acetic acid for one minute, then a 
quick rinse of deionized water. Sections were dipped in 95% alcohol, 100% alcohol, and 100% 
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alcohol for thirty seconds in each bath consecutively. Lastly, sections were placed in two Xylene 
baths for five minutes each then coverslipped.  
2.7.1.1 Cortical Injury Volume  
A total of 33 Sprague-Dawleys were evaluated for lesion volume (Table 2.2). Of those 33 rats, 9   
were part of the CCI + Vehicle group, 10 were part of Group 1 (CCI + DHF given 1-4 dpi), 8 were 
part of Group 2 (CCI + DHF given 2-6 dpi), 4 were part of Group 3 (CCI + DHF given 3-7 dpi), and 
4 were part of Group 4 (CCI + DHF given 5-9). 
Using a 4x objective, the injury site of the moderate controlled cortical impact was outlined. 
The area of the injury site from five sections was measured and added together. The total injury 
site area was multiplied by four and the sliced width of the section (i.e. 60µm) to calculate a 
mean in µm3 and then converted to mm3 to determine the volume of injury in mm3. 
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Immunohistochemistry 
Giemsa  Sham  
Vehicle + 
CCI 
Group 1 ,         
DHF 0-4 
dpi 
Group 2 ,          
DHF 2-6 
dpi 
Group 3,          
DHF 3-7 
dpi 
Group 4 ,          
DHF 5-9 
dpi 
Total 
Cortical Injury 
Volume 
0 9 8 8 4 4 33 
Hippocampal 
Cell Counts 
5 5 5 5 4 1 25 
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Table 2.2 Number of Animals Used from Each Treatment Group to Determine Lesion Volume 
and Hippocampal Cell Counts. Table showing the total number of animals used for Giemsa 
staining according to the animal treatment group and area of interest. 
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2.7.1.2 Hippocampal Neuronal Cell Counts  
Sections from a total of 25 rat brains (Table 2.2) were evaluated for hippocampal cell counts. 
Neuronal cell counts in the hippocampus were determined using the same brain tissue sections 
selected for measuring volume of injury site (i.e. -2.5 to -5.2 from Bregma). A stereological 
optical fractionator method was used to assess the number of neurons in the ipsilateral CA3, 
hilus, and granular region of the hippocampus. A total of 5 sequential sections 240um apart 
were assessed for each brain. These areas are vulnerable to TBI injury and can be easily 
quantified. Using a 4x objective, the area to be counted was outlined i.e. CA3, hilus, or granular 
region. A 60x oil immersion objective was used to count the cells in the outlined area. The 
Giemsa-stained neuronal nuclei cells with predetermined x, y intervals were counted using an 
optical dissector counting frame. The stage-stepping intervals that moved over the section were 
relative to the known area (a) of the counting frame. The sampling fraction (asf) is equal to the 
a (frame)/a (x,y step). The section thickness (t) was relative to the dissector height (h). Given 
the parameters, total cell counts could be estimated with n = ΣQ‾· t/h · 1/asf · 1/ssf. The ΣQ‾ is 
the number of cells counted and the ssf is the section-sampling fraction, which is 0.25. 
Neuronal cell counts in the CA3 and granular region were determined using the n = ΣQ‾· t/h · 
1/asf · 1/ssf method, while the entire outlined hilus region (area between granule cell layer and 
CA3/4 with scattered neurons) was scanned under 60x objective and each hilus neuron cell 
body was counted individually. The neurons that were counted all demonstrated clear nucleoli 
defined in a nuclear membrane.  
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2.7.2 Biotinylated Dextran Amine (BDA) Staining 
BDA is a commonly used neuronal tracer when injected into the nervous system. After 
injection, BDA can be taken up by cell bodies and dendrites of neurons then transported 
anterogradely or taken up by the axon terminals and transported retrogradely back to cell body 
(Xue et. al., 2004). High molecular weight BDA (10k) provides labeling of axons and terminals, 
while low molecular weight BDA (3k) provides labeling of neuronal cell bodies. It can later be 
visualized through the use of an avidin-biotinylated HRP, or ABC, procedure and enhanced with 
diaminobenzindine (DAB) (Reiner et. al., 2000). In this study BDA was used for anterograde 
labeling of inter- and intracortical axon sprouting in the cerebral cortex around the injury site. A 
total of 9 rats were studied for BDA labeling to asses axon sprouting (Table 2.3).  
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Sham Vehicle + CCI
Group 1 ,         
DHF 0-4 dpi
Group 2 ,          
DHF 2-6 dpi
Group 3,          
DHF 3-7 dpi
Group 4 ,          
DHF 5-9 dpi
Total
BDA- axon 
sprouting 1 2 0 0 5 1 9
VGlut1- 
synapse 2 3 3 3 3 2 16
Immunohistochemistry
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Table 2.3 Number of Animals used for Biotinylated Dextran Amine (BDA) and VGlut1 Labeling. 
Table showing the total number of animals used for biotinylated dextran amine (BDA) and 
VGlut1 labeling according to the animal treatment group. 
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The protocol for the use of biotinylated Dextran Amine (BDA) in inter- and intracortical 
neuronal labeling after stroke was successfully used by X. Liu et. al. (2010) and similarly used in 
this experiment. BDA was injected into the injury contralateral cortex 14 days post injury. Rats 
were placed in a stereotactic frame and a cranionectomy was performed on the injury 
contralateral side. A BDA solution consisting of 100nl (a 10% solution in 0.1 mol/L PBS, 10,000 
MW) was injected through a finely drawn glass capillary into a forelimb motor cortex with the 
stereotactic coordinates of 0.5, 1.5mm rostral to the bregma, 2.5 lateral to the midline, at a 
depth of 1.5 to 1.7 mm from the cortical surface and being administered for a duration of three 
minutes. Animals were sacrificed two weeks after BDA injection at 28 days post-TBI.  
After perfusion and fixation, a vibratome was used to cut 60 or 50 µm brain tissue sections from 
each brain. Four sections from each brain injected with BDA were used to detect labeling with 
relative coordinates of 1.2 to -2.0 from the bregma according to the Paxinos and Watson 
stereotaxic rat atlas (Paxinos & Watson, 1986). A mean pixel intensity, determined from the 
four sections of each BDA labeled brain, was used to analyze inter- and intracortical staining. 
The tissue sections were immunostained in the following manner: sections were rinsed with 
phosphate buffer saline (PBS) twice, five minutes each rinse and placed on shaker during rinses. 
Then sections were quenched with 3% hydrogen peroxide for one hour and placed on shaker. 
After one hour in hydrogen peroxide, sections were rinsed with PBS for ten minutes and placed 
on shaker. Due to the Biotin-conjugated antibodies, sections were then incubated with avidin-
biotin complex (ABC) for two hours. ABC was made 30 minutes in advance and made at a 1:200 
dilution in PBS. After ABC step, sections were washed again with PBS for ten minutes, three 
times, on shaker. A DAB solution was made with 10mg of DAB in 40ml of 0.1M phosphate 
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buffer saline and 17.5 µl of 30% hydrogen peroxide. The sections were incubated with DAB 
solution for five to fifteen minutes at room temperature while being monitored and controlled 
under a microscope. Reaction with DAB was stopped with PBS and additional washes with PBS. 
Tissue sections were then mounted onto slides and counterstained with Nissel.  
Nissel staining was achieved in the following manner: place mounted tissue sections in 75% 
alcohol for one minute two times. Then place sections in 0.1% Nissel for one minute. Next wash 
sections with running tap water. Differentiate by dipping sections in acid alcohol a few times. 
Acid alcohol solution consisted of 75% alcohol and a few drops of 2N hydrochloric acid. 
Evaluate color change. Place sections in 95% alcohol for one minute, then in 100% alcohol for 
one minute (two times), and then in Xylene for five minutes (two times). Coverslip sections with 
permount and glass cover.  
After Nissel staining, sections were examined by a light microscopy. Images were photographed 
at 10x and than evaluated with ImageJ program. A mean pixel intensity, determined from the 
four sections of each BDA labeled brain, was used to analyze inter- and intracortical staining.  
2.7.3  VGlut-1 fluorescent staining  
In the brain, specific vesicular glutamate transporters (VGLUTs) load glutamate into excitatory 
neurotransmitters into synaptic vesicles. More specifically, VGLUT1 is predominately found in 
the hippocampus. The regulation of VGLUT expression can affect glutamate release and may 
play a role in presynaptic plasticity (Hel et. al., 2009). 
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A total of 16 Sprague-Dawleys were evaluated for Vglut 1 staining (Table 2.3). After animal 
sacrifice, a vibratome was used to cut 60 or 50 µm brain tissue sections from each brain. Brain 
tissue sections spanning the rostro-caudal extent of the hippocampal dente gyrus area were 
selected for staining. These sections were relative to the coordinates of -2.5 to -5.2 from the 
bregma according to the Paxinos and Watson stereotaxic rat atlas (Paxinos & Watson, 1986). 
These selected tissue sections were immunostained with VGlut1 in the following manner: 
sections were rinsed with phosphate buffer saline (PBS) twice, five minutes each rinse and 
placed on shaker during rinses. Then sections were quenched with 3% hydrogen peroxide for 
one hour and placed on shaker. After one hour in hydrogen peroxide, sections were rinsed with 
PBS for ten minutes and placed on shaker. Tissue sections were blocked overnight at 4˚C on 
shaker in a blocking buffer that consisted of 5% normal horse serum and PBS + 0.3% triton. The 
following day (day 2 of procedure), the primary antibody, consisting of guinea pig anti-VGlut1 
(1:1000; Millipore, Temecula, CA) was placed on the tissue sections at 300µl per well/tissue. 
Sections were incubated at 4˚C on shaker for 48 hours. On day four of the procedure, sections 
were brought back to room temperature and rinsed with PBS + 0.3% triton for ten minutes 
three times. The sections were blocked again using the same blocking buffer as before (5% 
normal horse serum and PBS + 0.3% triton) for three hours on shaker. After three hours, the 
secondary antibody, consisting of Alex Fluor 568 goat anti-guinea pig IgG (1:1000, Life 
Technologies), was placed on sections at 4˚C on shaker overnight covered with tin foil. On day 
five of staining procedure, tissue sections were brought back to room temperature and washed 
with PBS for ten minutes, three times. Then the tissue sections were incubated with DAPI at a 
dilution of 1:1000 for 15 minutes on shaker. Again, tissue sections were washed with PBS for 
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ten minutes three times followed by a quick rinse with water twice. Tissue sections were 
mounted on glass slides and coverslipped with vectorshield sealed with nail polish and stored in 
a -20˚C freezer.  
After fluorescent staining, the hippocampus on the ipsilateral injury side was examined by a 
fluorescent microscope. Images were photographed at 4x. The intensity of staining was 
evaluated with ImageJ program. Mean pixel intensity was used to analyze exicitory synapse 
stained by VGlut1. 
2.8 Statistical Analysis 
 The data gathered from behavioral, cognitive, and immunohistochemistry procedures was 
analyzed using SPSS software. Data is presented as the mean and standard error of the mean. A 
one-way analysis of variance (ANOVA) followed by a post-hoc Fisher least significant and 
difference (LSD) test or the Duncan Multiple Range test was performed to identify significance 
between groups. Significance was determined by p-values less than 0.05.  
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Chapter Three – Results 
 
3.1 The Effect of 7,8-DHF Treatment on Motor Function 
The tests that evaluated behavioral and motor skills included the beam walk task and the 
rotarod. Training of beam walk task and rotarod was administered one day prior to CCI. Testing 
of behavioral/motor tasks occurred on days 1, 3, 5, and 7 post-CCI. An ANOVA was used to 
determine significance among all treatment groups, followed by a post hoc Fisher least 
significant difference (LSD) to determine the pairwise significant differences among group 
means.  
3.1.1 Beam Walk  
Using ANOVA, it was determined that there was an overall significant difference between all 
treatment group mean scores of the beam walk task on days 1 (p =.001), 3 (p =.001),  5 (p 
=.000), and 7 (p =.013) post-CCI. Post hoc comparisons, using Fisher LSD, were used to evaluate 
pairwise differences among group means.  
Post hoc comparisons of day 1 post-CCI of beam walk task showed that the Sham group mean 
(5.68 ± 1.53 seconds) was significantly shorter than the mean difference scores of the Group 1 
(9.32 ± 2.13 seconds, p = .036), Group 2 (11.53 ± 4.13 seconds, p = .002) , Group 3 (11.14 ± 2.05 
seconds, p = .004), Group 4 (10.20 ± 2.42 seconds, p = .030), and the CCI + Vehicle group mean 
(13.23 ± 5.40 seconds, p =.000). In addition, there was also a significant difference between 
Group 1 and the CCI + Vehicle group, p = .012, on day one post brain injury of beam walk task. 
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At the time of testing of day 1 post CCI of beam walk test, the only group to have received 7,8-
DHF treatment was Group 1.  
Post hoc comparisons of day 3 post CCI of beam walk task also showed similar results. The 
Sham group (3.97 ± .94 seconds) spent significantly less time to transverse the beam compared 
to Group 2 (7.47 ± 2.27 seconds, p =.009), Group 3 (7.95 ± 2.13 seconds, p =.003), Group 4 (7.76 
± 2.01 seconds, p =.012), and the CCI + Vehicle group mean (9.66 ± 4.12 seconds, p =.000). In 
addition, the CCI + Vehicle group continued to have a significant difference compared to the 
mean difference score of Group 1 (6.35 ± .79 seconds, p =.004).  
All animals continued to exhibit improvement on beam walk task on day 5 of testing. However, 
the Sham group (3.34 ± .90 seconds, p = .000), Group 1 (4.20 ± .42 seconds, p = .000), Group 2 
(5.04 ± .90 seconds, p = .008), and Group 3 (5.37 ± .50 seconds, p = .024) were all significantly 
different from the CCI + Vehicle group (7.15 ± 2.58 seconds, # p < .05). This trend of only Group 
4 (3.84 ± .39seconds) not having a significant difference compared to CCI + Vehicle group (4.85 
± 1.20 seconds, #p < .05) continued into day 7 of beam walk testing (Sham, 3.06 ± .78, p = .004; 
Group 1, 3.01 ± .46, p = .002; Group 2, 3.52 ± .544, p= .040; Group 3, 3.12 ± .35, p= .005).  
For all time points post CCI of the beam walk task, there was an improved score among all 
experimental groups (Figure 3.1).  However, 7,8-DHF treatment Group 1 performed significantly 
better at every time point of the beam walk task compared to CCI + Vehicle (*p < .05). 
Treatment Group 1 also had a mean score on day 7 of beam walk testing comparable to the 
Sham group (3.01 ± .46 , 3.06 ± .78 respectively). 7,8-DHF treatment Group 4 did perform better 
than the CCI + Vehicle treatment group but not enough to be significant at any time point (p > 
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.05). These results indicate that 7,8-DHF can provide neural protection after a TBI when starting 
administration one hour after injury, leading to better motor recovery and even possible 
extinction of motor deficits. 
3.1.2 Rotarod 
Using ANOVA, it was determined that there was an overall significant difference between 
treatment group mean scores of the Rotarod test on days 1 (p < .001), 3 (p =.001), and 5 (p 
=.074) post-CCI. Post hoc comparisons, using Fisher LSD, were used to evaluate pairwise 
differences among group means. Compared to all other treatment groups, the Sham group 
performed significantly better on day 1, 3, and 5 of Rotarod test (*p < .05). All animals that 
received a CCI, including those that received 7,8-DHF and Vehicle doses, improved in their 
ability to stay on the Rotarod at every time point; however, the only significance was in relation 
to those animals that did not receive a CCI (Figure 3.1).  No difference was found among injured 
animals.  
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Figure 3.1 Administration of 7,8-DHF Starting One Hour after TBI Significantly Improved Beam 
Walk Results but 7,8-DHF Did Not Improve Rotarod Results. (A) In the beam walk test, injured 
animals with vehicle treatment took a longer time to transverse the beam than sham group, 
demonstrating motor deficits (#p<.05). Among injured animals, 7,8-DHF treatment group 1 
spent less time to transverse the beam than the vehicle group, indicating improved motor 
function (*p<.05). 7,8-DHF treatment group 4 did not show a difference compared to vehicle. 
(B) In the rotarod test, all injured animals spent less time on rotating wheel than the sham 
group, indicating motor deficits (*p<.05). 
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3.2 The Effect of 7,8-DHF Treatment on Cognitive Functions  
The cognitive tests used included the Morris Water Maze (MWM) and fear conditioning test. 
The MWM was administered on days 12-15 post CCI. Latency was tested days 12-15 and the 
probe trial was administered on day 16 post CCI with a 24 hour delay after the last latency test. 
The fear conditioning test was administered days 8 and 9 post CCI. An ANOVA was used to 
determine significance among all treatment groups, followed by a post hoc Fisher LSD to 
determine the pairwise significant differences among group means in the probe test of the 
MWM and for fear conditioning results. The Duncan Multiple Range test was used to determine 
specific group differences in the latency testing of MWM. 
3.2.1 Morris Water Maze (MWM): Latency  
A group x day split-plot ANOVA test was used to analyze MWM tests. The Duncan Multiple 
Range test was used to determine specific group differences. Comparisons of days 13, 14, and 
15 post-CCI of MWM showed that the Sham group was significantly different compared to all 
other groups (*p<.05). On day 14 of the MWM latency testing, 7,8-DHF treatment Group 2 
mean (35.82 ± 7.89 seconds) and Group 3 mean (35.10 ± 3.46) were also significant compared 
to Group 4 (47.24 ± 10.40 seconds, *p < .05). On day 15 of MWM latency testing, both Group 1 
and Group 2 performed better and were able to reach the submerged platform sooner than 
Group 3, Group 4, and CCI + Vehicle group; however, the differences between means was not 
significant (p > .05) (Figure 3.2). Overall, administration of 7,8-DHF starting two and three days 
after TBI appears to provide some mild protection against hippocampal spatial memory and 
prefrontal cortex learning  deficits.  
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Comparisons of proximity to platform in MWM during latency testing indicated that there was a 
significant difference on day 15 of testing (p < .05). This was determined to be the Sham Group 
(22.25 +/- 2.50, *p<.05), being statistically closer in proximity to hidden platform than all other 
groups [Group 1 (28.85 +/- 5.25), Group 2 (28.75 +/- 2.36), Group 3 (32.69 +/- 4.27), Group 4 
(31.40 +/- 7.99), and CCI + Vehicle group (32.35 +/- 7.18)]. 7,8-DHF treatment Group 2 had a 
closer proximity to the platform days 13-15 of MWM compared to all other animals that 
received a CCI; however, this was not significant (p > .05). This trend in closer proximity to the 
platform by Group 2 suggests that administration of 7,8-DHF starting two days after brain injury 
may provide some protection against deficits in hippocampal learning and memory (Figure 3.2). 
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Figure 3.2 Administration of 7,8-DHF Starting Two and Three Days after TBI Improves Morris 
Water Maze Latency (A) In MWM latency testing, the injured animals with vehicle treatment 
took longer to find the hidden platform compared to sham on days 13-15 dpi, demonstrating 
cognitive deficits (*p<.05). On day 14 dpi, 7,8-DHF treatment Group 2 and Group 3 had shorter 
latency times compared to Group 4 (*p < .05), indicating some improved memory function. 7,8-
DHF treatment groups 1, 2, 3 and 4 did not have difference compared to vehicle group. (B) In 
the MWM proximity to platform during latency testing, sham animals had a smaller proximity 
to hidden platform than the injured vehicle treatment group on day 15 post injury (*p<.05), 
indicating cognitive deficits after brain injury. All 7,8-DHF treatment groups did not show a 
difference compared to vehicle.  
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3.2.2 Morris Water Maze (MWM): Probe Test 
ANOVA results indicated that there was a significant difference between treatment group 
means for the MWM probe test, time spent in the goal quadrant, or 4th quadrant, where the 
platform was previously placed for latency testing on days 12-15 post CCI (p < .05). Further 
evaluation using the post hoc comparisons, LSD, determined that the average time that Group 4 
(24.46 ± 6.91 seconds, *p < .05) spent in the goal quadrant was significantly less than the Sham 
Group (37.38 ± 5.84, p = .000), Group 1 (36.19 ± 5.53, p = .001), and Group 3 (32.51 ± 2.28, p = 
.020). The CCI + Vehicle group mean (25.04 ± 7.68) was significantly less than (*p < .05) all other 
groups except Group 4 (Figure 3.3).  
During the probe test, the proximity to the missing platform was also measured. ANOVA results 
indicated that there was a significant difference between treatment group means for the MWM 
probe test, proximity to where the platform was previously placed for latency testing on day’s 
12-15 post CCI (p = .002). Further evaluation using the post hoc comparisons, LSD, determined 
that the average proximity that Group 1 (43.79 ± 6.99, *p = .019) and Group 3(44.54 ± 4.51, *p 
= .048) had to the once placed platform was significantly less than the CCI + Vehicle group 
(51.04 ± 9.55). Group 2 (47.20 ± 4.64) and Group 4 (47.44 ± 10.16) also had mean proximities 
less than the CCI + Vehicle group; however, these were not significant (p > .05) (Figure 3.3). In 
addition, the Sham group’s mean proximity (36.41 ± 3.47) during the probe test was also 
significantly less compared to all groups (p < .05). The results from the probe portion of the 
MWM testing indicate that 7,8-DHF administration starting at one hour or three days after 
brain injury can provide protection against hippocampal memory loss associated with TBI.  
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Figure 3.3 Administration of 7,8-DHF Starting One Hour and Three days after TBI Spent More 
Time in Goal Quadrant and Closer Proximity to Missing Platform. (A) In probe trial tests, 
injured animals with vehicle treatment spent much shorter time in the goal quadrant compared 
to sham, demonstrating significant memory deficits (*p<.05). Among injured animals, 7,8-DHF 
treated Group 1, 2, and 3 spent longer time in the goal quadrant that the injured vehicle group 
demonstrating improved memory function (*p<.05). 7,8-DHF treatment Group 4 did not show 
difference compared to Group 2 and vehicle group. (B) Uninjured animals were closer to the 
location of the previously placed platform than all injured animals, indicating significant 
memory deficits (*p<.05). Among injured animals, 7,8-DHF treatment groups 1 and 3 had closer 
proximities than injured vehicle group, indicating improved memory deficits (*p<.05). 7,8-DHF 
treatment groups 2 and 4 did not show difference compared to vehicle.  
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3.2.3 Fear Conditioning: Contextual and Cued 
Fear Conditioning was measured through contextual and cued approaches. ANOVA scores for 
the contextual aspect of fear conditioning indicated that there was a difference between the 
sham group mean (37.20 ± 10.68) and CCI + vehicle group mean (16.29 ± 4.08, *p<.05), 
indicating that there is a deficit in hippocampal dependent memory function. Looking at the 
trend in the freezing percentages a slight pattern can be observed. Animals that received 7,8-
DHF had a slightly higher freezing percentage during the contextual testing of fear conditioning 
compared to the CCI + Vehicle group, indicating there may be an improvement in hippocampal 
dependent memory function (Figure 3.4). 
The ANOVA results for the cued portion of the fear conditioning test indicated that there was 
significant difference among groups (p < .05). Further post hoc, LSD, analysis showed that  
injured animals with vehicle treatment froze less than sham, demonstrating significant 
amygdala dependent memory deficits (*p<.05). Among injured groups, 7,8-DHF treatment 
groups 1 and 2 had a slightly higher but not significant freezing percentage compared to the CCI 
+ Vehicle group, indicating there may be some improvement in amygdala dependent memory 
function. 7,8-DHF treatment group 3 did not show a difference compared to vehicle and froze 
significantly less than sham (*p<.05) (Figure 3.4). 
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Figure 3.4: Administration of 7,8-DHF After TBI May Protect Against Hippocampal Dependent 
Memory Loss. (A) In the contextual part of fear conditioning test, injured animals with vehicle 
treatment froze less than sham, demonstrating significant hippocampal dependent memory 
deficits (*p<.05). Among injured groups, all animals that received 7,8-DHF had a slightly higher 
but not significant freezing percentage compared to the CCI + Vehicle group, indicating there 
may be some improvement in hippocampal dependent memory function. (B) In the cued 
portion of the fear conditioning test, injured animals with vehicle treatment froze less than 
sham, demonstrating significant amygdala dependent memory deficits (*p<.05). Among injured 
groups, 7,8-DHF treatment groups 1 and 2 had a slightly higher but not significant freezing 
percentage compared to the CCI + Vehicle group, indicating there may be some improvement in 
amygdala dependent memory function. 7,8-DHF treatment group 3 did not show a difference 
compared to vehicle and froze significantly less than sham (*p<.05). 
 
 
 
 
 
68 
 
3.3 The Effect of 7,8-DHF Treatment on Neuroprotection 
 Due to the fact that Giemsa dye is able to stain the phosphate groups of DNA (Prainsack et. al., 
2014), it was used to determine the cerebral cortex lesion volume induced by CCI and the 
number of neurons that were present in different areas of the hippocampus. 
3.3.1 Cortical Lesion Volume 
The ANOVA results of the lesion volumes indicated that there was a significance among groups 
(p < .05). Further post hoc, LSD, analysis showed 7,8-DHF treatment Group 2 (1.13 ± 1.03) had a 
reduced lesion volume compared to the vehicle group (2.80 ± 1.64, *p = .019), indicating 
neuronal protection. 7,8-DHF treatment Group 1 (1.52 ± 1.23, *p = .040) and Group 2 (1.13 ± 
1.03, *p = .014) had smaller lesion volumes compared to Group 4 (3.33 ± 1.39) (Figure 3.5). 
These results indicate administration of 7,8-DHF starting one hour and two days after a TBI can 
provide neuronal protection against cortex tissue loss after a TBI. 7,8-DHF treatment Group 3 
did not have a difference compared to vehicle. 
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Figure 3.5 Cerebral Cortex Lesion Volume Significantly Reduced in Treatment Groups That 
Received 7,8-DHF Administration One Hour and Two Days After Injury Incident. (A) 7,8-DHF 
treatment Group 2 had a reduced lesion volume compared to the vehicle group, indicating 
neuronal protection (*p < .05). 7,8-DHF treatment Group 1 and Group 2 had smaller lesion 
volumes compared to Group 4 (*p < .05). These results indicate administration of 7,8-DHF 
starting one hour and two days after a TBI can provide neuronal protection against cortex tissue 
loss after a TBI. 7,8-DHF treatment Group 3 did not have a difference compared to vehicle. (B) 
Cortex tissue damage on the ipsilateral side of CCI animal that received 7,8-DHF within one 
hour of brain injury. (C) Cortex tissue damage on the ipsilateral side of CCI animal that received 
vehicle. 
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3.3.2 Hippocampal Neuronal Cell Counts 
Giemsa staining allowed for the neurons to be counted in the CA3, hilus, and granular region 
(Figure 3.6). Areas were outlined with 4x objective and cells were counted with a 60x oil 
immersion objective. Neuronal cell counts in the CA3 and granular region were determined 
using the n = ΣQ‾· t/h · 1/asf · 1/ssf method, while the entire outlined hilus region (area 
between granule cell layer and CA3/4) was scanned under 60x objective and each hilus neuron 
cell body was counted individually. Neuronal cell counts in the CA3 of the hippocampus 
indicated that the injured animals with vehicle treatment (26,660.33 ± 623.75) had less amount 
of neurons compared to the sham group (33,074.23 ± 2839.32), indicating neuronal cell loss in 
CA3 (*p=.022). There was no difference among 7,8-DHF treatment animals and vehicle treated 
animals (p > .05) (Figure 3.6). In the hilus region, post hoc, LSD, revealed that injured animals 
with vehicle treatment (2,651.97 ± 73.07) had a smaller amount of cells compared to the sham 
group (4,580.10 ± 595.02, *p=.010), indicating neuronal cell loss. Group 2 (4,203.97 ± 1,269.09, 
*p = .032) was significantly higher than the CCI + Vehicle group, indicating neuronal protection. 
7,8-DHF treatment Group 1 (3,736.89 ± 459.35), Group 3 (3,227.49 ± 693.81), and Group 4 
(2,612.6) were not different from vehicle group (Figure 3.7). In the granular region, LSD analysis 
revealed that 7,8-DHF treatment Group 1 (160,995.32 ± 5,901.52, *p = .03), Group 2 
(160,280.05 ± 20,562.50, *p = .034), and Group 3 (164,269.26 ± 36,402.41, *p = .025) had a 
larger amount of cells compared to the CCI + Vehicle group (129,721.43 ± 10,997.14), indicating 
neuronal protection. Group 4 (120,965.64) did not have a difference compared to vehicle 
(Figure 3.7). These results indicate that 7,8-DHF administration starting at one hour, two days, 
or three days post brain injury could provide neuronal cell protection.  
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Figure 3.6 Giemsa Staining of Neurons in Hippocampus. (A) Giemsa stained neurons in the CA3 
region of hippocampus. (B) Giemsa stained neurons in the hilus region of the hippocampus. (C) 
Giemsa stained neurons in the granular region of the hippocampus.(D) Neuronal cell count CA3 
indicated that the injured animals with vehicle treatment had less amount of neurons 
compared to the sham group, indicating neuronal cell loss in CA3 (*p<.05). There was no 
difference among 7,8-DHF treatment animals and vehicle treated animals (p > .05) (Figure 3.6).  
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Figure 3.7 Administration of 7,8-DHF Starting Day Two After TBI had an Effect on Neuronal 
Cell Counts Hilus and Granular Region. (A) In the hilus region, post hoc, LSD, revealed that 
injured animals with vehicle treatment had a smaller amount of cells compared to the sham 
group (*p<.05), indicating neuronal cell loss. Group 2 was significantly higher in cell numbers 
than the CCI + Vehicle group, indicating neuronal protection (*p<.05). 7,8-DHF Groups 1,3, and 
4 did not show a difference compared to vehicle. (B) In the granular region, 7,8-DHF treatment 
Group 1, 2, and 3 had a larger amount of cells compared to the CCI + Vehicle group (*p<.05), 
indicating neuronal protection. 7,8-DHF Group 4 did not show a difference compared to vehicle 
These results indicate that 7,8-DHF administration starting at one hour, two days, or three days 
post brain injury could provide neuronal cell protection.  
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3.4 The Effect of 7,8-DHF Treatment on Neural Plasticity 
3.4.1 Biotinylated Dextran Amine (BDA) 
When injected into the nervous system, biotinylated dextran amine (BDA) can provide detailed 
neuronal labeling. After injection, BDA can be taken up by cell bodies and dendrites of neurons 
then transported anterogradely (Xue et. al., 2004). In this study BDA was used for anterograde 
labeling of inter- and intracortical axon sprouting in the cerebral cortex around the injury site.  
BDA was injected through a finely drawn glass capillary into the forelimb motor contralateral 
cortex for duration of three minutes 14 days post injury. Animals were sacrificed two weeks 
after BDA injection at 28 days post-TBI. Four sections from each brain injected with BDA were 
used to detect labeling with relative coordinates of 1.2 to -2.0 from the bregma according to 
the Paxinos and Watson stereotaxic rat atlas (Paxinos & Watson, 1986). A mean pixel intensity, 
determined from the sections of each BDA labeled brain, was used to analyze inter- and 
intracortical staining.  
Through SPSS software, an ANOVA was used to analyze the mean relative density percentages 
of treatment groups. This revealed that there was a trend of slightly higher, but not significant, 
density readings, which may indicate increased intracortical axon sprouting in the ipsilateral 
injured cortex of animals that received 7,8-DHF treatment starting three days after brain injury 
(Figure 3.9).  
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Figure 3.8 BDA Labeled Intracortical Axon Sprouting of Ipsilateral Injury Cortex. (A) BDA 
labeling highlighted a slight trend that the axons of animals treated with 7,8-DHF three days 
after injury had slightly higher, but not significant, density readings, which may indicate 
increased intracortical axon sprouting. (B) Intracortical axon sprouting in the ipsilateral injured 
cortex of a Group 3 brain section. (C) Intracortical axon sprouting in the ipsilateral injured 
cortex of a CCI + vehicle brain section. 
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3.4.2 Vglut1 
In the brain, specific vesicular glutamate transporters (VGLUTs) load glutamate into excitatory 
neurotransmitters into synaptic vesicles. The regulation of VGLUT expression can affect 
glutamate release and may play a role in presynaptic plasticity (Hel et. al., 2009). In this study 
Vglut1 was used to label synapse in the ipsilateral hippocampus. After fluorescent staining, 
images were photographed at 4x.  
Only the CA3 region of the hippocampus showed Vglut1 staining. This region was further 
evaluated with ImageJ program. Mean pixel intensity was used to analyze exicitory synapse 
stained by VGlut1. ANOVA results indicated that there was no statistical difference between 
groups, p > .05. However, Group 4 (39.88 ± 6.46) had a higher mean score than Group 1 (29.01 
± 16.97), Group 2 (31.73 ± 9.87), Group 3 (33.48 ± 5.53) and the CCI + Vehicle group (33.07 ± 
5.73), indicating that some neuronal plasticity is taken place in CA3 of the hippocampus (Figure 
3.9). 
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Figure 3.9 VGlut-1 Labeling of the Hippocampus (A) A slight, but not significant, increase of 
VGlut-1 staining in treatment group receiving 7,8-DHF starting day five post brain injury 
compared to other brain injury groups, indicating that there may be some neuronal plasticity. 
(B) Image of VGlut1 fluorescent labeling of CA3  
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Chapter Four – Discussion 
 
Since the discovery of 7,8-DHF, it has been documented to provide neuroprotection and 
neuroplasticity in various neurological diseases and disorders (Liu et. al., 2012). 7,8-DHF has a 
much longer half-life and can easily pass the BBB, making it also a possible alternative in 
treating TBI (Zeng et. al., 2012; Wu et. al., 2014). This study addressed the effects of 7,8-DHF on 
neuroprotection and neuroplasticity after TBI when administered for 5 doses/daily starting at 0, 
2, 3, and 5 days after a CCI. Sensorimotor function was evaluated with beam walk test and 
rotarod. Morris Water Maze (MWM) and fear conditioning test were used to analyze cognitive 
function. Brain sections were processed for Giemsa histological staining to calculate cortical 
lesion volume and the total number of surviving neurons. Parallel sections were also processed 
for BDA staining to identify axon sprouting in the injured cortex and VGlut-1 staining to assess 
presynaptic plasticity in the hippocampal region. 
Sensorimotor tests revealed that animals receiving 7,8-DHF, starting one hour after brain injury, 
performed significantly better and were able to transverse the beam in a shorter length of time 
than vehicle treated animals at all time points. By day seven of the beam walk test, animals that 
had received 7,8-DHF treatment beginning one hour to three days after CCI performed better 
than those that started receiving 7,8-DHF at 5 days post injury. Our findings are similar to Wu 
et. al. (2014) who demonstrated that four doses of 20mg/kg of 7,8-DHF given to mice ten 
minutes after a CCI could significantly reduce neurobehavioral deficits. Results from this study 
and previously mentioned study coincide with a therapeutic window that could protect against 
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neurodegeneration. It is within the first hour of brain injury that caspases, the mediators of 
apoptosis, can be found in the thalamus and subcortical regions (Keane et. al., 2001). Cortical 
projection neurons in thalamus can be observed undergoing apoptosis in the following 24 hours 
(Natale et. al., 2002) and diffuse neurodegeneration in the ipsilateral cortex and thalamus has 
been found to peak between 48-72 hours. Damage to these cortical and thalamic neurons can 
result in motor dysfunction (Hall et. al., 2005).  The results from this study indicate that the 
administration of 7,8-DHF starting at one hour after injury and before the peak of cortical and 
thalamic neurodegeneration at 48-72 hours can provide optimal neuroprotection against 
secondary damage and significantly decrease motor dysfunction due to TBI. 
According to Hamm et. al. (1994) the rotarod is sensitive enough to evaluating motor function 
in even mild TBI cases. Animals that received a CCI in our study exhibited similar lengths of time 
on the rotarod at all time points. This is contrary to what was observed by the Wu et. al. (2014) 
study that found 7,8-DHF administration after brain injury resulted in better performance on 
Rotarod compared to vehicle treated animals. It is important to note that all CCI animals in our 
study did improve in their ability to stay on the rotarod over time, indicating that the rotarod 
was able to measure motor function and a natural motor recovery process can occur after brain 
injury. Conflictions in findings could be due to the 4x greater dose of 7,8-DHF administered in 
the Wu et. al. study and the type of animal used in the CCI model. 
Previous animal models have concluded that 7,8-DHF can reduce cognitive deficits that result 
from synaptic loss in the hippocampus and cortex. Improved spatial learning and memory in the 
MWM was observed in an Alzheimer’s mouse model (Castello et. al., 2013) and in an aged rat 
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model that both administered 5mg/kg of 7,8-DHF doses for several days (Zeng et. al., 2012). 
Our results from the MWM latency testing did not corroborate previously mentioned studies 
that report 7,8-DHF improves spatial learning. Treatment groups that received 7,8-DHF starting 
one hour and two days after brain injury only showed a trend of better latency times than other 
CCI injury groups. However, animals that started receiving 7,8-DHF treatment at one hour or 
three days after brain injury preformed significantly better on the MWM probe test. These 
results indicate that the administration of 7,8-DHF starting at one hour or three days after TBI 
can provide protection against hippocampal memory loss. This treatment regiment coincides 
with neurodegeneration in the hippocampus where apoptosis can start to occur within the first 
24 hours (Zhou et. al., 2012) and peak between 48-72 hours after brain injury (Hall et. al., 
2005).   
According to the time frame of neurodegeneration, 7,8-DHF administration starting two days 
after brain injury should have also provided protection against hippocampal memory loss; 
however, we did not see this in our results. The hippocampus is one of the main areas of BDNF 
production (Lee et. al., 2002) and it has been demonstrated that BDNF levels increase after 
brain injury (Chiaretti et. al., 2003). In addition, the mature form of BDNF can bind to p75NTR 
receptor when there are high concentrations of BDNF (Boyd & Gordon, 2003). Perhaps the poor 
protection in memory loss observed in animals that received 7,8-DHF starting at two days post 
injury reflects the activation of the apoptotic pathway via the BDNF/p75NTR due to 7,8-DHF and 
BDNF competing for the TrkB receptors. In addition, the differences observed in spatial learning 
compared to Castello et. al. and Zeng et. al. could also be a result of the duration of 7,8-DHF 
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treatment. This study provided 7,8-DHF for five days where it was given for two weeks in the 
Alzheimer’s model and for 34 days in aged rats.  
In further evaluation of cognitive function, contextual results from the fear conditioning test 
also highlighted a trend that 7,8-DHF may provide some relief to hippocampal memory deficits 
observed with TBI, especially when 7,8-DHF administration begins one hour after injury.  The 
cued portion of the fear conditioning test indicated that amygdala induced memory deficits 
were not significantly affected by 7,8-DHF treatment. Our findings contradict the Andero et. al. 
(2011) study that found that mice receiving 7,8-DHF had improved non-hippocampal memory, 
suggesting 7,8-DHF targets TrkB receptors in the amygdala and are critical for fear learning. 
Both studies used the same dose of 7,8-DHF; however, Andero et. al. (2011) used a mouse 
model that inflicted foot shock with tone for five trials , where we only conducted one trial.  
Contusion measurements indicated that the administration of 7,8-DHF starting one hour or two 
days after brain injury resulted in significantly smaller lesion volumes compared to vehicle 
treated animals. This reflects reduced infarct volumes observed in a mouse stroke model that 
received 7,8-DHF  two hours after injury (Jang et. al., 2010). Wu et. al. (2014) also found a 
significant reduction in lesion volume of ipsilateral hemisphere when 7,8-DHF was administered 
ten minutes after a CCI in mice. As mentioned previously, our results coincide with a possible 
therapeutic window that could protection against neurodegeneration seen within the first hour 
of brain injury (Keane et. al., 2001) and peaking between 48-72 hours (Hall et. al., 2005).   
The effect that 7,8-DHF has on neuroprotection after TBI was also evaluated through 
examination of neuronal cell numbers in different regions of the hippocampus, an area most 
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vulnerable following brain injury. In the Baldwin et. al. (1997) study that looked at total number 
of neurons in the CA3 region of the rat hippocampus after a CCI, they predict a therapeutic 
window of less than 24 hours after brain injury to provide neuroprotective treatment. It is 
within this time period that they saw the most neuron cell death. According to their prediction, 
7,8-DHF starting at one hour after brain injury should have resulted in more CA3 neuronal cells 
compare to other treatment groups in our study. Our findings of the CA3 region did not follow 
this prediction. There was no significant difference in CA3 cell numbers among 7,8-DHF 
treatment or vehicle groups. Comparatively, our CCI model inflicted a smaller contusion than 
the Baldwin et. al. (1997) study, which could explain our CA3 neuronal cell numbers. 
Despite the fact that there was no significant neuronal protective effect on neuronal survival in 
the CA3 region, neuronal cell counts in the hippocampal hilus and the granular regions did show 
significant differences among 7,8-DHF treatment groups and the CCI + Vehicle group. In the 
hilus region, animals that received 7,8-DHF administration starting two days after injury had 
significantly more neuronal cells than the vehicle group. Neuronal cell numbers were also 
significantly higher in the granular region of 7,8-DHF treatment groups that started receiving 
doses one hour, two days, and three days post injury compared to the vehicle group. The 
results from the neuronal cell counts reflect 7,8-DHF’s effect on two different mechanisms that 
occur after TBI: neurodegeneration and neurogenesis. Again, the treatment regiment starting 
at one hour, two or three days after brain injury overlaps the time course of neurodegeneration 
in the hippocampus. However, it also coincides with TBI induced neurogenesis where it has 
been documented that there is increased cell proliferation after injury, (Chirumamilla et. al., 
2002; Dash et. al., 2001; Sun et. al., 2005) peaking at two days after brain injury (Sun et. al., 
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2005). The higher neuronal cell counts in the granular region suggest neuroprotective and 
neurogenic effects of 7,8-DHF after TBI.  
In this study, biotinylated dextran amine (BDA) and VGlut1 were used to determine if varied 
times of 7,8-DHF administration after TBI had any effect on neuronal plasticity. BDA labeling 
highlighted a slight trend that the axons of animals treated with 7,8-DHF three days after injury 
had slightly more, but not significant, intracortical axon sprouting in the ipsilateral injured 
cortex compared to vehicle animals. This could reflect a better treatment window for 
neuroplasticity. However, due to variances in staining at site of injection, further analysis would 
need to be conducted to normalize labeling, ensuring that density readings were a result of 
labeled axon sprouting and not excess dye. VGlut1 results also highlighted a trend of neuronal 
plasticity taking place in the CA3 region of the hippocampus with the administration of 7,8-DHF. 
The area of VGlut1 staining is the same region where immature neurons extend their axons to 
create connections with the pyramidal neurons in CA3 (Bohlen und Halbach, 2007). These 
connections can occur within 4-10 days of birth (Hastings and Gould, 1999) which could explain 
why there was a slight increase in VGlut-1 staining in 7,8-DHF treatment groups that received 
treatment starting on day five post brain injury compared to treatment groups that received 
7,8-DHF starting at one hour, two, and three days post injury.  
Results from this study indicate that the administration of 7,8-DHF starting one hour after brain 
injury can provide neuroprotection evidenced by attenuated motor and cognitive impairments, 
reduce lesion volume and increased neuronal cells in the granular cell layer of the 
hippocampus. Administration of 7,8-DHF starting two days and three days post TBI also 
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exhibited some protection against neurodegeneration. Neurogenesis was not directly assessed 
in this study; however, we found indications that 7,8-DHF may promote neurogenesis via the 
increased number of neurons in the granule cell layer. Our BDA and VGlut-1 labeling highlighted 
a possible trend that neuronal plasticity could be enhanced with 7,8-DHF administration 
starting day five post injury. Further animals in the treatment groups that received 7,8-DHF 
starting day three and five post brain injury could provide the statistical significance needed to 
clearly indicate 7,8-DHF’s effect on neuronal plasticity. Additional staining with immature and 
mature neuronal markers could indicate the effect that 7,8-DHF has on neurogenesis after TBI.  
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